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Major depressive disorder (MDD) is a complex, heterogeneous disorder 
characterised by a pathological distortion of emotional mood. There is evidence 
of both genetic and environmental risk factors for MDD, and gene-environment 
interactions may play a particularly important role. Clinically, MDD is defined by 
patients meeting a number of diagnostic criteria. However, the heterogeneous 
nature of the disorder can make MDD difficult to diagnose, especially as it 
shares close similarities with other psychiatric illnesses such as bipolar disorder. 
Another clinical problem is that antidepressants, the first line of treatment for 
MDD, are ineffective in a significant proportion of patients.  The projects in this 
thesis address four aims: (i) the identification of novel gene-environment 
interactions which may increase risk for MDD; (ii) the identification of diagnostic 
biomarkers for MDD; (iii) the identification of biomarkers for the prediction of 
treatment response to antidepressants; and (iv) the identification of 
transcriptional changes associated with antidepressant treatment and successful 
therapeutic response.   
 Utilising a model of early life stress in two inbred mouse strains, we 
investigated the transcriptional effects of maternal separation. The top stress by 
strain interaction was found in the telomerase RNA component gene (Terc). We 
also found that a single nucleotide polymorphism in TERC (rs10936599), 
previously identified as a predictor of telomere length, interacted with childhood 
neglect to predict MDD in a human case-control cohort.  
A study investigating differences in the transcription of inflammatory 
cytokines in the blood of MDD patients, bipolar disorder patients and controls, 
revealed disorder-specific differences in chemokine (C-C motif) ligand 24 and C-
C chemokine receptor type 6 which specifically differentiated MDD patients. 
Furthermore, we found that transcription of tumour necrosis factor and its targets 
in the inflammatory cytokine pathway, and DNA methylation in interleukin-11 
could be used to predict antidepressant response amongst MDD patients. 
Moreover, transcription of ATP-binding cassette sub-family F member 1 was 
found to increase on antidepressant treatment, with the magnitude of change 
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1.1 Major Depressive Disorder 
The studies described in this thesis examine the causes of major depressive 
disorder (MDD), and the utility of peripheral cytokine biomarkers as aids for 
clinical diagnosis and treatment selection. This section summarizes the current 
research findings relating to the diagnosis, epidemiology, aetiology, and treatment 
of MDD, as well as the potential utility of cytokine biomarkers. 
 
1.1.1 Diagnosis of Major Depressive Disorder 
 
MDD is a complex heterogeneous disorder which is characterised by a 
pathological distortion of emotional mood (Jones et al., 2002). MDD is 
diagnosed when patients meet a number of clinical diagnostic criteria, as detailed 
in the Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV) and 
International Classification of Diseases 10 (ICD-10). According to the DSM-IV, 
an individual is diagnosed with MDD if they show persistently lowered mood, 
loss of interest or pleasure for two weeks or more, along with at least four 
accompanying symptoms. Accompanying symptoms can include: changes in 
appetite or weight, sleep changes, psychomotor agitation or retardation, loss of 
energy, feelings of worthlessness or excessive inappropriate guilt, diminished 
concentration, and recurrent thoughts of death or suicide. Additionally, 
symptoms must not meet the criteria for a mixed episode, the effects of a 
substance or general medical condition, or be caused by bereavement. 
Furthermore, the symptoms must cause clinically significant distress and cause an 
impairment in social, occupational or other areas of functioning. In addition to 
categorical diagnosis, clinical scales have also been developed to measure 
! 15 
depressive symptoms and their severity. Examples include the Beck Depression 
Inventory (BDI; Beck & Steer, 1984), Hamilton Rating Scale for Depression 
(HAM-D; Hamilton, 1960), and the Montgomery–Åsberg Depression Rating 
Scale (MADRS; Montgomery & Asberg, 1979). 
 
1.1.2 Epidemiology of MDD 
MDD is estimated to affect 350 million people worldwide, and the World 
Health Organisation (WHO) predicts MDD to become the second leading cause 
of disability globally by 2020 (Murray & Lopez, 1996; WHO 2012). The 
prevalence of MDD is twice as high amongst women as men (Nolen-Hoeksema, 
1990; Blazer et al., 1994; Kessler et al., 1994); a feature hypothesized to relate to 
sex differences in hormones, coping strategies, and tendencies to seek medical 
help (Ernst & Angst, 1992; Nolen-Hoeksema, 2000; Kessler et al., 2003). 
Sociodemographic factors have been found to influence lifetime prevalence rates 
of MDD and age of onset, with high-income countries reporting higher lifetime 
prevalence rates of MDD (14.6%) and a later age of onset (25.7 years), relative to 
middle-to low-income countries which show a lower lifetime prevalence rate 
(11%) and earlier age of onset (24 years) (Bromet et al., 2011). Interestingly, 
studies focusing on high-income countries only find that those with lower 
socioeconomic status show increased rates of MDD, relative to those with higher 
levels of education and income (Lorant et al., 2003).  
MDD is a recurring, chronic disorder, with an estimated 80% of those 
diagnosed with MDD experiencing two or more episodes during their lifetime 
(Mueller et al., 1999; Hollon et al., 2006). Furthermore, duration of major 
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depressive episodes, severity of episodes, neurobiological factors, socioeconomic 
status, and comorbities have all been found to moderate the rate of episode 
recurrence (Keller et al., 1992; Lorant et al., 2003; Spijker et al., 2004; Hollon et 
al., 2006; Holma et al., 2008). 
 
1.1.3 Comorbidity with MDD 
 
MDD is associated with high rates of comorbity, both with psychiatric and 
physical disorders. Studies have revealed that over 50% of MDD patients also 
qualify for the diagnosis of an anxiety disorder (Löwe et al., 2008). MDD patients 
are also more likely to suffer from substance abuse, eating disorders, post-
traumatic stress, impulsive control disorder, obesity, type-2 diabetes, 
cardiovascular disease, thyroid disease and osteoarthritis (Katon et al., 2007; 
Farmer et al., 2008; Harvey & Ismail, 2008). 
 
1.1.4 Genetic Causes of MDD 
Studies have revealed that MDD tends to aggregate in families, with one meta-
analysis reporting a nearly three-fold increase in susceptibility to MDD amongst 
first-degree relatives of MDD patients (Sullivan et al., 2000). Similarly, high 
concordance rates for MDD have been revealed amongst twins, suggesting that 
genetic factors or a closely shared environment may moderate the risk of MDD. 
To tease out the contribution of shared environment and shared genetics in 
MDD, twin studies comparing concordance rates between monozygotic twins 
(sharing 100% of the same genes) and dizygotic twins (sharing 50% of the same 
genes) have been employed. Such studies assume that if all twins share the same 
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environmental upbringing, higher concordance rates between monozygotic twins, 
relative to dizygotic twins, suggest that genetic factors increase the susceptibility to 
a trait, which is what has been found for MDD (Kendler et al., 1992). 
Furthermore, sophisticated modeling has been used to calculate heritability 
estimates. ‘Heritability’ refers to the proportion of between-individual differences 
in vulnerability to a trait explained by the additive effect of genes (Keers et al., 
2011). Results from twin modelling studies have revealed a broad range of 
heritability estimates for MDD (between 29-70%), with broad estimations 
attributed to differences in study design (clinical versus community based studies) 
and sample selection (recurrent versus non-recurrent, early versus late-onset) 
(Kendler et al., 1992; Sullivan et al., 2000; McGuffin et al., 2007). All of these 
twin studies however, confirm that a substantial proportion of risk to MDD in the 
population relates to genetic background.  
Despite twin studies suggesting MDD has a strong genetic component, 
genome-wide association studies (GWASs) have not been able to identify 
particular genes associated with the presence of MDD (e.g. Sullivan et al., 2009; 
Lewis et al., 2010; Muglia et al., 2010). This includes a recent “mega-analysis” 
comparing the genes of 9240 MDD cases and 9519 controls which did not 
identify genes robustly associated with MDD (Major Depressive Disorder 
Working Group of the Psychiatric GWAS Consortium, 2013). Results therefore 
suggest that a ‘missing heritability’ exists, whereby the high heritability estimates 
from twin studies do not translate to the identification of differences at the 
molecular genetic level. This may be the result of numerous factors, including: 
the ineffective definition of the phenotype; the presence of many SNPs with very 
small effect sizes contributing to MDD; the existence of copy number variations; 
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epigenetic factors; and gene-environment interactions (Zuk et al., 2012). 
 
1.1.5 Environmental Causes of MDD 
The most robust environmental factor associated with MDD is stress (Hosang et 
al., 2012). ‘Stress’ describes any environmental change, internal or external, that 
disturbs the maintenance of homeostasis (Pacák & Palkovits, 2001). Stressful life 
events (SLEs) refer specifically to events that produce a strain on an adult’s life, 
such as the loss of a job, marital separation, or loss of a loved one (Hosang et al., 
2012). Severe SLEs are predicted to occur on average every 3 to 4 years in adult 
life (Brown et al., 1987). Studies have revealed that SLEs such as the end of a 
relationship or loss of a loved one, double the risk of MDD (Mazure et al., 
1998). One study estimates that approximately 20% of individuals who 
experience a severe SLE will develop MDD (Brown et al., 1987). SLEs also 
predict the recurrence of depressive episodes in already diagnosed MDD 
patients (Kessler, 1997). Subsequently, there are clear links between SLEs, MDD 
pathophysiology and episode precipitation. 
Early stressful life events (eSLEs) in the form of childhood abuse 
(physical, sexual and emotional) and neglect (physical and emotional) have also 
been linked to an increased likelihood of MDD in adulthood, in conjunction 
with long-lasting changes in brain structure and functionality, and an exacerbated 
stress response (Kaufman & Charney, 2001, Meaney 2001, Essex et al, 2002, 
Fisher et al., 2013). It is thought that eSLEs alter neurobiological circuitry during 
‘sensitive’ periods of development, evoking these enduring physiological and 
psychological effects (Meaney, 2001).  
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Interestingly, it has also been found that eSLEs correlate with SLEs in 
adulthood, and predict future abusive relationships and financial difficulties 
(Brown et al., 2008; Zielinski et al., 2009). This is in some agreement with the 
‘kindling hypothesis’ which states that stress preceding the onset of MDD 
symptoms is usually severe (e.g. childhood maltreatment), and sensitizes the 
individual to more frequent future stresses and depressive episodes (Monroe & 
Harkness, 2005). Consequently, it has been proposed that the more ‘distal’ 
events occurring in childhood may be important in the prediction of SLEs in 
adulthood and the occurrence of MDD (Keers & Uher, 2012). 
 
1.1.6 Gene-environment interaction causes of MDD 
Studies have suggested that gene-environment interactions may play an important 
role in the pathophysiology of psychiatric disorders (Lesch, 2004; van Os et al., 
2008). Gene-environment interactions may be particularly pertinent in MDD, 
where SLEs are known to increase the susceptibility of some individuals to 
MDD, but not others. The presence of gene-environment interactions in MDD 
may also explain our inability to identify genotypes associated with the disorder 
from GWASs, as it may be the interaction between genes and environment 
which is more relevant to its pathophysiology (Uher et al., 2008). Furthermore, 
this could explain the disparity between high heritability estimates from twin 
studies and the failure to identify genes in MDD GWASs, i.e. the ‘missing 
heritability’ phenomenon (see Section 1.1.4.). No studies have yet investigated 
gene-environment interactions on a genome-wide scale, as a very large sample 
size is predicted to be required to detect interaction effects after correction for 
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multiple testing. Consequently, novel susceptibility genes for MDD, which may 
exist as part of a gene-environment interaction, have not yet been identified. 
However, four candidate genes have previously been found to interact with SLEs 
to predict MDD, these include: the serotonin-transporter-linked polymorphic 
region, brain derived neurotrophic factor, corticotrophin-releasing hormone 
receptor 1, and FK506-binding protein (Keers & Uher, 2011).  
 
1.1.6.1 Serotonin-transporter 
Perhaps the most notable, yet highly contentious example of a gene-environment 
interaction for MDD was based on results from pioneering research carried out 
by Caspi and colleagues in 2003, identifying an interaction between the 
serotonin-transporter-linked polymorphic region (5-HTTLPR) and SLEs. In 
Caspi’s study they found that increasing numbers of SLEs increased depression 
severity scores, but was moderated by a functional variant in the serotonin 
transporter gene, 5-HTTLPR. It was found that those homozygous for the S-
allele (known to produce lower levels of RNA transcript) suffered from 
significantly higher levels of depression than those homozygous for the higher-
expressing L-allele, in response to an increasing number of SLEs (Caspi et al., 
2003). This suggests that the serotonin transporter gene may act as a moderator 
of SLEs and subsequently an individual’s susceptibility to MDD. Although, there 
have been further studies supporting Caspi’s findings (e.g. Karg et al., 2011), 
others have not (e.g. Risch et al., 2009, Fisher et al., 2012, Tomoda et al., 2013) 
which may relate to differences in study design (e.g. cross-sectional versus 
longitudinal, and self-reports versus interviewer-assessed).  
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More recent studies suggest that perhaps the association between the 5-
HTTLPR and stress is more robust when the stress occurs in childhood (Karg et 
al., 2011). Studies have shown that childhood neglect and maltreatment, 
particularly sexual abuse interacts with the 5-HTTLPR to predispose to MDD in 
adulthood (Uher et al., 2011; Fisher et al., 2013).  
 
1.1.6.2 Brain Derived Neurotrophic Factor 
A non-synonymous SNP, rs6265, in the brain derived neurotrophic factor gene 
(BDNF) which results in the substitution of a valine for a methionine amino acid 
(known as the “Val66Met” polymorphism), has been found to interact with SLEs 
to predict MDD status (Kim et al., 2007). BDNF is involved in the survival, 
development and function of neurons (Huang & Reichardt, 2001). Met carriers 
are known to exhibit reduced secretion of BDNF (Egan et al., 2003), show 
smaller hippocampal volumes (Bueller et al., 2006), and exhibit increased 
vulnerability to MDD in response to childhood abuse (Kim et al., 2007; Aguilera 
et al., 2009). Additionally, there’s evidence that Val66Met interacts with 5-
HTTLPR and SLEs to predict MDD as part of a gene x gene x environment 
interaction (Kaufman et al., 2006; Kim et al., 2007).  
 
1.1.6.3 Corticotropin releasing hormone receptor 1 
 A key receptor in the stress response, corticotropin releasing hormone receptor 
1 (CRHR1), has been found to moderate susceptibility to MDD. Haplotypes 
within the receptor which binds the corticotropin-releasing hormone have been 
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found to interact with the experience of childhood maltreatment to predict both 
cortisol levels (Tyrka et al., 2009) and MDD status (Bradley et al., 2008; 
Polanczyk et al., 2009; Kranzler et al., 2011). 
 
1.1.6.4 FK506-binding protein 
FK506-binding protein (FKBP5) is a downstream mediator of glucocorticoid 
receptor signalling involved in protein folding, trafficking and immunoregulation 
(Ising et al., 2008). One SNP (rs1360780) has been found to affect the 
expression of the gene, resulting in increased glucocorticoid receptor resistance 
(a reduced sensitivity to ligand-binding and mediation of downstream signalling) 
and greater stress-induced increases in cortisol (Ising et al., 2008). rs1360780 has 
additionally been found to interact with childhood trauma to predict MDD, with 
T-carriers being more vulnerable to the effects of early maltreatment (Appel et 
al., 2011; Zimmerman et al., 2011). 
 
1.1.7 Epigenetic Causes of MDD 
Epigenetic processes, namely DNA methylation and histone acetylation, act in 
addition to the DNA sequence as a second layer of information mediating the 
regulation of functional gene expression (Bell et al., 2011). Epigenetic 
modifications are influenced by a combination of factors, including genomic and 
environmental factors (e.g. stressful life events), and as such act as one molecular 
mechanism through which gene-environment interactions occur (Meaney et al., 
2001). DNA methylation is a stable yet reversible modification to cytosine 
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nucleotides on the DNA strand, and recent studies have identified possible 
differences in DNA methylation in the brains and blood of MDD patients 
relative to controls (Sabunciyan et al., 2012; Zill et al., 2012). Furthermore, 
antidepressants and mood-stabilizers have been found to evoke epigenetic 
changes, and research suggests these changes may be important in mediating 
antidepressant response in rodents (Menke et al., 2012; Nasca et al., 2012).  
 
1.2 Neurobiological Causes of MDD 
Despite failures to identify the causes of MDD from the genetic level, studies 
investigating protein differences, drug effects, and structural brain differences hint 
towards some of the possible neurobiological events contributing to MDD 
(Lanfumey, 2008). Further work is still needed to better understand the precise 
neurobiological changes involved in MDD. Nevertheless, several neurobiological 
theories dominate the literature surrounding MDD; although they are by no 
means mutually exclusive, four of these theories are discussed next. 
 
1.2.1 The monoamine theory of MDD 
The first theories on the neurobiological causes of MDD stem from studies on 
the treatment of the disorder, as opposed to its cause. Imipramine and iproniazid 
were two compounds developed in the 1950s for their antihistaminergic and 
antitubercular effects respectively (López-Muñoz & Alamo). Coincidentally, both 
compounds were discovered to improve patient mood and were subsequently 
approved by the Food and Drug Administration (FDA) for the treatment of 
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MDD. Whilst imipramine blocked serotonin and noradrenergic reuptake at the 
synapse, iproniazid acted as a monoamine oxidase inhibitor, reducing catabolism 
of the monoamines (serotonin and norepinephrine) within the synaptic cleft (Maj 
et al., 1984), see Figure 1.1. Therefore, this evidence suggested that increasing 
monoamine neurotransmission could reduce depressive symptoms (Charney, 
1998). This has been the basis of antidepressant drug development to-date, with 
behavioural responses to these compounds in mice also forming the basis of 
novel antidepressant drug screening (Powell et al., 2012, see Appendix 1 for full 
review article). 
Naturally, the discovery that monoamines may play a role in ‘anti-
depression’ has also led to the hypothesis that a reduction in monoamine 
neurotransmission may be involved in the pathophysiology of MDD (Charney, 
1998; Elhwuegi, 2004). If this were the case, we would expect monoamine 
inhibitors such as reserpine, to induce depressive symptoms (Brodie et al., 1957). 
However, studies have revealed mixed results, with some subjects demonstrating 
increases in depressive symptoms in response to reserpine, whilst other studies 
found reserpine to have antidepressant effects (Baumeister et al., 2003). 
Furthermore, there is no conclusive evidence of increased serotonin metabolites 
such as 5-Hydroxyindoleacetic acid (5HIAA) amongst MDD patients, which we 
might expect if these patients were showing reduced serotonin neurotransmission 
as a result of rapid catabolism. However, there is strong evidence of a reduction 
of 5HIAA in suicide attempters, suggesting it may be involved in the impulsive 
suicidality component of MDD found in some patients (Asberg &  Träskman, 
1981; Brown  & Linnoila, 1990). Consequently, although there is no dispute that 
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monoamines play a key role in the treatment of MDD, it remains unclear as to 





Figure 1.1:  Monoaminergic neurotransmission and antidepressant action. The 
picture shows two pre-synaptic neurons and a post-synaptic neuron. The 
serotonin transporter (5-HTT), noradrenaline transporter (NAT), and 
monoamine oxidase (MAO) all represent targets of antidepressant drugs. 
Antidepressant action results in increased binding of serotonin and 





1.2.2 Dysregulation of the hypothalamic-pituitary-adrenal 
(HPA) axis 
The HPA axis is the physiological construct governing the stress response. When 
a mammal is exposed to a stressor, a sequence of events occurs, starting at the 
paraventricular nucleus of the hypothalamus, where corticotrophin 
releasing hormone (CRP) and arginine vasopressin (AVP) are released 
(Lanfumey, 2008). CRP and AVP then bind to receptors on the anterior 
pituitary, causing the release of adrenocorticotropic hormone (ACTH) which 
binds to receptors in the adrenal cortex, culminating in the release of the stress 
hormone cortisol (Lanfumey, 2008), see Figure 1.2. It is estimated that 
approximately half of patients suffering from MDD show abnormal, excessive 
activation of the HPA axis, making cortisol levels one of the most robust markers 
for MDD (Curtis et al., 1976; Hellhammera et al., 2009).  Excessive activation of 
the HPA axis has also been found in humans and mammals exposed to SLEs, 
particularly eSLEs, suggesting HPA dysregulation may represent a link between 
stress and MDD (Meaney et al., 2001).  
 
1.2.3 Neurotrophins theory of MDD 
The hippocampus is a brain region involved in learning, memory and emotional 
processing (Strange et al., 1999). Evidence suggests that MDD patients may 
exhibit volumetric decreases in the hippocampus relative to controls (Sheline et 
















Figure 1.2: The hypothalamic pituitary adrenal (HPA) axis. A summary of the 




Although there are numerous explanations as to the cause of this decreased 
hippocampal volume (e.g. excessive cortisol release), the most popular theory 
relates to the neurotrophins (Krishnan & Nestler, 2008). Neurotrophins are a 
family of proteins involved in the survival, development and function of neurons 
(Huang & Reichardt, 2001). BDNF has been found to be lower amongst MDD 
patients, which may contribute to lower hippocampal volumes (Karege et al., 
2002). Furthermore, studies have observed increases in BDNF in response to 
antidepressants (Shimizu et al., 2003), and direct infusion of BDNF into the 
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brain has been shown to induce antidepressant effects in animal models 
(Shirayama et al, 2002). It is hypothesized that BDNF is also responsible for 
promoting the development of neural progenitor cells and hippocampal 
neurogenesis in response to treatment, with the time taken for this to occur 
hypothesized to correspond to the ‘therapeutic lag’ between administration of 
antidepressants and the alleviation of symptoms (Boldrini et al., 2009). 
 
1.2.4 Cytokine theories of MDD 
Cytokines represent a group of cell-signalling molecules which, in the periphery, 
aid inflammatory processes and the immune system to form co-ordinated 
responses to infection (Dantzer et al., 2008, see Figure 1.3). However, evidence 
suggests that they also have potent effects on the brain and may be involved in 
the pathophysiology of MDD. 
 
1.2.4.1 Cytokines and the brain 
Peripheral cytokines can act centrally by accessing the brain through vagal nerve 
activation or by crossing the blood-brain barrier via ‘leaky’ regions or as a result 
of active transport (Banks et al., 1995). Cytokines are also constitutively 
expressed within the central nervous system and can function both as neural 
protectors and agents facilitating neurodegeneration (Miller et al., 2009). 
Cytokines have been found to influence a multitude of systems within the brain, 
affecting neurotransmitter metabolism, neuroendocrine function and neural 
plasticity (Miller et al., 2009).  
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1.2.4.1.1 Cytokines and neurotransmitters 
Cytokines have been found to affect both the synthesis of neurotransmitters and 
neurotransmitter-receptor interactions. For instance, cytokines have been found 
to activate the enzyme indoleamine 2,3 dioxygenase (IDO), which metabolises 
tryptophan, the amino acid precursor to serotonin (Fujigaki et al., 2006).  
Subsequently, the break down of tryptophan culminates in a reduction in the 
availability of tryptophan for serotonin synthesis (Young & Leyton, 2002). 
Interestingly, it has also been shown that pharmacological inhibition of IDO 
prevents the precipitation of sickness behaviours in mice, on treatment with 
lipopolysaccharide, suggesting the action of cytokines on IDO may be critical for 
behavioural changes associated with MDD (O’Connor et al., 2008). Cytokines 
have also been found to affect the functionality of neurotransmitter transporters. 
For instance, TNF has been shown to enhance serotonin transporter function in 
human placental cell lines (Mossner et al., 1998), rat neuronal cell lines and in 
mouse brain (Zhu et al., 2006).  
 
1.2.4.1.2 Cytokines and neuroendocrine function 
Acute administration of cytokines has been found to stimulate the HPA axis and 
subsequently cortisol release (Miller et al., 2009). It is hypothesized that chronic 
high levels of cytokines may impair the negative feedback loops in the HPA axis 
resulting in persistently high levels of cortisol release (Besedovsky et al., 1996). 
This furthermore evokes changes to the glucocorticoid receptor including 
reduced expression, and a reduced responsiveness to cortisol, as reported 
amongst MDD patients (Pariante & Miller, 2001).  
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1.2.4.1.3 Cytokines and neural plasticity 
Putative links have also been formed between peripheral immune activation and 
hippocampal volume (Miller et al., 2009). For instance, peripheral 
lipopolysaccharide has been associated with heightened intra-hippocampal levels 
of TNF and IL1, which inhibits expression of BDNF and its receptors, resulting 
in reduced hippocampal volumes (Wu et al., 2007). 
 
1.2.4.1.4 Cytokines and the pathophysiology of MDD 
The first theories linking inflammatory processes to MDD arose as a result of the 
high rates of comorbidity between MDD and other medical conditions [see 
Section 1.1.3]. A growing body of evidence suggests that cytokines such as the 
chemokines, interferons, interleukins and the tumor necrosis factor family may 
have effects of the brain which are important in the pathophysiology of MDD 
(Dantzer et al., 2008). Patients with MDD who are otherwise healthy have been 
found to exhibit increased levels of proinflammatory cytokines (e.g. tumour 
necrosis factor, interleukin-6) and their receptors in peripheral blood, 
cerebrospinal fluid, and within the brain itself (Lanquillon et al., 2000; Pandey et 
al., 2011). However, this information alone does not allow us to discern whether 
abnormal cytokine levels are a cause or effect of MDD, but other lines of 
evidence do suggest that changes in cytokines may represent the cause of MDD 
symptoms. For instance, studies have repeatedly confirmed that the pro-
inflammatory cytokine interferon-alpha (IFN-a), used in the treatment of hepatitis 
and cancer, elicits depressive symptoms in a large proportion of patients (~40%), 
along with altered neurotransmitter metabolism, neuroendocrine function, and 
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responsiveness to antidepressant pharmacotherapy (Bonaccorso et al., 2002; 
Raison et al, 2006). These findings linking cytokines to MDD are further 
supported by animal studies. For instance, rodents injected with immunoreactive 
substances, such as lipopolysaccharide, display ‘sickness behaviours’ consisting of 
behaviours analogous to those exhibited by MDD patient, for example 
anhedonia, decreased activity, cognitive dysfunction, and altered sleep (Konsman 
et al., 2002). These observations therefore imply that endogenous cytokines and 
their modulation of the innate immune system are involved in the 
pathophysiology of MDD. 
 
 
Figure 1.3: The inflammatory cytokine pathway. A picture showing the complex 
interactions between immune cells, orchestrated through the release of different 




1.2.5 Mouse models of MDD 
 
Some features of MDD show similarities to mouse behaviours, and, as such, 
mouse models have been developed to improve our understanding of the 
pathophysiology and treatment of depressive symptoms. Mouse behaviours such 
as immobility in the forced swim test and tail suspension tests are thought to 
mirror behavioural despair present in human depression (Porsolt et al., 2001). 
Whereas, anhedonia is measured by a decrease in sucrose consumption in the 
sucrose preference test in mouse (Papp et al., 1991) and by an increase in latency 
to approach and eat food in the novelty-suppressed feeding test (Dulawa & Hena, 
2005); see Powell et al., (2012a) as found in Appendix A for more details.  
One of the main advantages of using mice in researching a genetic 
disorder such as MDD is that over 95% of the mouse genome is similar to the 
human genome (The Jackson Laboratory, 2013). Furthermore, the utilisation of 
inbred strains and knockouts allow us to test the influence of different genetic 
backgrounds in response to specific changes to the environment (Powell et al., 
2012a). In particular, mouse models can be used to investigate: the effects of 
stress on behaviour (Meaney et al., 2001), the presence of stress by gene 
interactions (Kember et al., 2012), the antidepressant properties of novel 
compounds (Jacobson and Cryan, 2007), and the presence of pharmacogenetic 
interactions (Malki et al., 2010).  
Two common mouse protocols used to model MDD phenotypes in mice 
include the chronic mild stress, and maternal separation protocol, which are both 
based on the assumption that stressful events are involved in the cause of MDD 
(Deussing, 2006). The chronic mild stress (CMS) model of MDD involves 
exposing animals to numerous mild and unpredictable stressors (Willner, 2005). 
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Stressors can include temperature changes, changes in amounts of food and 
water, and changes to their cage mates (Willner et al., 1992). It is hypothesized 
that the CMS protocol models the daily unpredictable stresses faced in adult 
human life, which may contribute to MDD (Deussing, 2006). The CMS protocol 
induces behavioural, neurochemical changes and changes in responses to reward, 
thought to parallel those changes occurring in MDD patients (Willner, 2005). 
The maternal separation protocol specifically models early life stress and involves 
young pups being separated from their dam (mother) for between 1 and 24 
hours, either as a single separation or part of a repeated separation over 
numerous days (Meaney et al., 2001). This protocol induces long-lasting 
increases in anxiety-like behaviours, increased stress-responsiveness in 
adulthood, and long-lasting molecular changes in the brain (Meaney et al., 2001; 
Kember et al., 2012). 
 
1.3 Treatments for MDD 
 
According to the National Institute for Health and Care Excellence (NICE), a 
combination of pharmacotherapy and high intensity psychological therapy (e.g. 
cognitive behavioural therapy) is recommended for the treatment of moderate to 
severe MDD (NICE, 2004). Here we discuss some common pharmacotherapies 
used to treat MDD, as well as cognitive behavioural therapy, alternative 
psychological therapies, and electroconvulsive therapy. 
 
1.3.1 Pharmacotherapies used to treat MDD 
 
Antidepressants are the first line of treatment for MDD. As described in Section 
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1.2.1,  antidepressants target the monoamines, which are a group of 
neurotransmitters, derived from aromatic amino acids that have crucial roles in 
emotion, arousal and cognition (D’Souza & Craig, 2008). Antidepressants are 
understood to evoke their effects through increasing the neurotransmission of 
monoamines, particularly serotonin and noradrenaline, across the synapse 
(Charney, 1998). There are ten classes of antidepressant drugs commonly used 
to treat MDD, however, two of the most commonly prescribed classes are the 
selective serotonin reuptake inhibitors and tricyclics (Lawrenson et al., 2000). 
 
1.3.1.1 Selective Serotonin Reuptake inhibitors 
 
Selective serotonin reuptake inhibitors (SSRIs) are compounds which selectively 
block the serotonin transporter at the pre-synaptic neuron. This results in 
reduced reuptake of serotonin, allowing more to cross the synapse and bind to 
postsynaptic receptors (Charney et al., 1998). Although the main use of SSRIs is 
in the treatment of MDD, they are also used to treat generalised anxiety disorder, 
obsessive compulsive disorder, eating disorders and premature ejaculation (Stone 
et al., 2003). The main advantage of SSRIs is their more targeted nature. Unlike 
the “richer” pharmacology of the older tricyclics which affect numerous receptor 
and transporter types, SSRIs more selectivity target the serotonin transporter, 
resulting in lower rates of reported side effects (Lawrenson et al., 2000).  
An example of a commonly prescribed SSRI is escitalopram, its structure 
is shown in Figure 1.4. This drug has the highest affinity amongst all SSRIs for 
the serotonin transporter, and consists of a single active S-enantiomer. 
Escitalopram has been claimed to have more potent antidepressant effects than 
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the closely related racemic mixture citalopram (Montgomery et al., 2001). 
 
 




Tricyclics are named as such due to their three-ringed structure, see Figure 1.5. 
This class of antidepressant is particularly efficacious in the treatment of 
depression with melancholic features (Perry, 1996). Due to the richer 
pharmacology of these drugs (i.e. the fact they target a broad range of receptors 
and transporters), they are associated with a greater occurrence of side effects, 
but can also be used in the treatment of a broader range of ailments than other 
antidepressants such as SSRIs (Lawrenson et al., 2000). As well as their use in 
MDD and anxiety disorders, tricyclics have also been prescribed for use in 
chronic pain, Tourette’s syndrome, irritable bowel syndrome, narcolepsy and 
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eating disorders, amongst others (Gillman, 2007). 
An example of a commonly prescribed tricyclic antidepressant is 
nortriptyline, its structure is shown in Figure 1.5. Nortriptyline is a second-
generation tricyclic antidepressant with a particularly high affinity for the 
noradrenaline transporter, with a lesser effect on serotonin and dopamine 
reuptake (Gillman, 2007).  
 
 
Figure 1.5: The chemical structure of nortriptyline 
 
1.3.2 Psychological Therapies for MDD 
 
Psychological therapies for MDD include cognitive behavioural therapy, 
interpersonal therapy, psychoanalysis and mindfulness. Cognitive behavioural 
therapy (CBT) is a form of psychological intervention which employs theory 
from behavioural and cognitive realms to tackle psychological disorders (Schacter 
et al, 2010). It works by changing maladaptive thinking, mood, and subsequently 
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behaviour. Studies have suggested CBT can be as effective as monotherapy 
antidepressant treatment, with CBT and antidepressant therapy combined being 
the most effective form of treatment (Keller et al., 2000).  
Other psychological therapies include interpersonal psychotherapy (IPT), 
which is a short course of therapy aimed at dealing with interpersonal issues 
underlying MDD (Frank, 1971). Alternatively, psychoanalysis is therapy focused 
on Freud’s theories on the importance of early childhood experiences and 
unconscious internal conflicts (Frank, 1971). Furthermore, of increasing interest 
as a novel therapy for MDD is ‘mindfulness’. Mindfulness is thought to be 
effective for the treatment of MDD by redirecting patients’ attention to the 
present moment, as opposed to ruminating over past negative thoughts (Segal et 
al., 2013). 
 
1.3.3 Electroconvulsive Therapy 
 
Electroconvulsive therapy (ECT) involves the precipitation of seizures in patients 
through the application of an electric shock. NICE recommends ECT only in 
severe MDD, as it is has been linked to brain damage and memory loss (NICE, 
2004). Nevertheless, ECT has been found to be effective in treating MDD, and 
particularly efficacious in treating MDD in patients who show “treatment-
resistance”; i.e. those who fail to respond to numerous forms of pharmacological 
and psychological therapies. (Pagnin et al., 2004; Mayberg et al., 2005). There is 
limited understanding as to how ECT works, but the short-lived seizures may 
help to ‘jump start’ the brain, disrupting pathological brain circuitry and 
correcting neurochemical and blood-flow abnormalities (Mayberg et al., 2005).  
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1.4 Problems with diagnosis and treatment selection for 
MDD  
As discussed in Section 1.1.1., MDD is currently diagnosed based on patients 
meeting a number of “clinical characteristics” such as reporting lowered mood, 
loss of interest or pleasure (anhedonia), and sleep disturbances (American 
Psychiatric Association, 2000). However, due to the heterogeneous nature of 
MDD, it shares overlapping clinical characteristics with other disorders, which 
increases the risk of misdiagnosis. Furthermore, even after correct diagnosis 
there are still issues over which treatment is best for an individual (Uher et al., 
2010). 
 
1.4.1 Misdiagnosis between Bipolar Disorder and MDD 
 
Both MDD and bipolar disorder (BPD) are considered “mood disorders”, 
sharing common aetiologies and clinical manifestations (Jones et al., 2002). 
Similarly to MDD, BPD patients experience episodes of depression (e.g. 
lowered mood, loss of interest or pleasure, loss of energy), however BPD 
patients additionally experience episodes of mania (e.g. expanded self-esteem, 
increased distractibility, talkativeness; American Psychiatric Association, 2000). 
The diagnostic problem exists when BPD patients enter clinic pre-morbid for 
manic symptoms, which is commonly the case due to the often later onset of 
mania, and more frequent occurrence of depressive episodes in BPD (Lewis et 
al., 2003; Perlis et al., 2005). The pre-manic BPD patient will subsequently meet 
all the clinical criteria for MDD, be misdiagnosed as suffering from MDD, and 
be treated with antidepressants. Monotherapy antidepressant treatment given to 
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BPD patients increases their risk of antidepressant induced mania and cycle-
acceleration which can have damaging effects on disease prognosis (Wehr & 
Goodwin, 1979; Altshuler et al., 1995). Therefore, ways to improve the 
objectivity and specificity of clinical diagnosis (e.g. establishing disorder-specific 
biomarkers) would prove valuable in differentiating MDD from other related 
disorders. 
 
1.4.2 Ineffective treatment 
 
Another major clinical problem relates to the ineffective treatment of MDD. It is 
estimated that despite antidepressants being given as the first line of treatment for 
MDD, approximately two thirds of patients fail to respond to the first 
antidepressant prescribed (Gibson et al., 2010). Furthermore, one third fail to 
respond to multiple forms of antidepressant therapy (Gibson et al., 2010). This 
lag between diagnosis and the initiation of effective treatment prolongs the 
suffering of patients and increases the opportunity for suicide attempts. There 
are four proposed routes to improving the efficacy of treatment. Firstly, the 
identification of biomarkers might allow us to predict whether an individual is 
likely to respond better to one type of antidepressant over another, or whether 
they may be more suited to alternative forms of therapy such as CBT (Hepgul et 
al., 2013). Secondly, adjuvant therapies may compliment the actions of 
antidepressants, increasing their efficacy. For instance, its been found that the 
tumour necrosis factor antagonist infliximab may be a useful adjuvant for 
improving response in treatment-resistant MDD patients (Raison et al., 2013). 
Thirdly, antidepressant therapy combined with psychological therapies may 
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increase responsiveness, above that obtained with antidepressant treatment alone 
(Keller et al., 2000). Finally, new therapies targeting different biological systems 
may simply be more efficacious, and are yet to be discovered (e.g. Catena-
Dell'Osso et al., 2012). 
 
1.5. Biomarkers for MDD 
 
A biomarker is defined as a ‘characteristic that is objectively measured and 
evaluated as an indicator of normal biologic processes, pathogenic processes or 
pharmacologic responses to a therapeutic intervention’ (Atkinson et al., 2001). 
Biomarkers in psychiatry might offer a more objective way of diagnosing a 
disorder and selecting for the most appropriate treatment. In the case of a 
heterogeneous, polygenic disorder like MDD the hunt for biomarkers is 
particularly complex. 
Biomarker information at the genetic, transcriptomic and proteomic 
biological system levels may provide distinct and clinically useful information 
relating to MDD. Genotypes are stable, constant features that influence systemic 
physiological function throughout development and can predispose to certain 
disease states. Genomic information can therefore be used as state predictors of 
long-lasting functional differences in the brain (Meyer-Lindenberg et al., 2006), 
disease manifestation (Janssens & Duijn, 2008) and clinical responses to 
therapies (Kamali & Wynne, 2010). However, the dynamic and environmentally 
sensitive nature of cellular gene expression means that transcriptional and 
proteomic biomarkers may not only function as baseline state predictors, but 
could also potentially be used in conjunction with changes in behavioural traits as 
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a prospective measure of MDD prognosis (Riedmaier & Pfaffl, 2013). This is of 
particular clinical interest if early transcriptional or proteomic changes are found 
to precede behavioural changes relating to symptom severity or early response to 
antidepressant drugs.  
 
1.5.1 Inflammatory Cytokines as biomarkers in MDD 
 
As discussed in Section 1.2.4., inflammatory cytokines may play a role in the 
pathophysiology of MDD. Furthermore, due the fact that cytokines have access 
to the brain but are peripherally accessible, through migration across the blood-
brain barrier, they may possess useful biomarker properties relating to MDD 
(Banks et al., 1995). Here we will summarise recent literature pertaining to the 
cytokines at each system level (genetic, transcriptomic, proteomic) and 
demonstrate how they might be used to inform clinical decisions regarding the 
diagnosis and treatment of MDD. 
 
1.5.1.1 Cytokine biomarkers for MDD diagnosis 
 
As discussed in Section 1.1.3, no single gene has yet been robustly associated 
with MDD based on results from genome-wide association studies (GWASs) 
(Major Depressive Disorder Working Group of the Psychiatric GWAS 
Consortium, 2013). However, candidate gene studies suggest that single 
nucleotide polymorphism (SNP) differences in inflammatory-related genes may 
mediate susceptibility to MDD and, as such, future polygenic signatures 
incorporating this information may have useful diagnostic capabilities. 
Specifically, MDD case-control studies have revealed differences in genes coding 
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for interleukin 1B, interleukin 6, interleukin 10, and tumour necrosis factor 
(Clerici et al., 2009; Haastrup et al., 2012; Altamura et al., 2010; Jun et al., 2003; 




IL-1β is a member of the IL-1 cytokine family, encoded by the IL1B gene at 
location 2q14 of chromosome 2 (Yu et al., 2003). IL-1β is an important pro-
inflammatory cytokine which has a role in coordination of the immune response 
and regulation of cell proliferation, differentiation and apoptosis (Baune et al., 
2010). IL1B variants have been associated with decreased function in the 
amygdala and anterior cingulate cortex (Baune et al., 2010). These brain regions 
are involved in memory, emotional processing and reward mechanisms, and 
impaired functioning in each of these neural pathways have been implicated in 
the manifestation of MDD symptoms (Hamilton et al., 2012). A genotypic 
combination of homozygosity for the -31T allele (rs1143627) and -511C 
(rs16944) within IL1B has been associated with recurrent MDD, whereas 
heterozygosity at both sites is more common in controls (Borkowska et al. 2011). 
Furthermore, patients diagnosed with MDD who are homozygous for the -511C 
allele tend to have higher levels of depression severity (Yu et al., 2003). At the 
transcriptional level, IL1B has been reported to be higher in MDD patient blood 
relative to controls (Tsao et al., 2006; Cattaneo et al., 2012). However, there are 
mixed results at the protein level, with the latest meta-analysis suggesting IL-1B 





The human interleukin-6 gene (IL6) is organised into 5 exons and 4 introns on 
the short arm of chromosome 7 (Clerici et al., 2009). IL-6 is a pleiotropic 
cytokine which plays an important role in the acute phase response and chronic 
inflammation (Barnes et al., 2011). A SNP, rs1800795, in the promoter region 
has been associated with differential levels of IL-6 transcription and plasma 
concentrations. Those homozygous for the G-allele are known to produce higher 
levels of IL-6 and show higher levels of depression following interferon-a and 
ribavirin treatment (Bull et al., 2009). Furthermore, studies have consistently 
shown higher levels of IL-6, both at the transcriptional level (Tsao et al., 2006; 
Cattaneo et al., 2012), and at the protein level (Lanquillon et al., 2000; Alesci et 
al., 2005; Raison et al., 2006; Yang et al., 2007; Clerici et al., 2009; Miller et al., 
2009; Su et al., 2009; Howren et al., 2009; Dowlati et al., 2010; Hiles et al., 2012; 
Liu et al., 2012) amongst MDD patients relative to controls. Serum levels of IL6 
have also been shown to significantly correlate with the severity of MDD 




The anti-inflammatory properties of IL-10 are well described, with its main role 
being that of preventing damage to the host during infection (Pierson & Liston, 
2010). IL-10 is produced by B-cells and T-cells, and works to suppress the action 
of T-cells during inflammation (Pierson & Liston, 2010). The gene encoding IL-
10 maps to the 1q31-1q32 region on chromosome 1 and it is highly 
polymorphic, with the biallelic polymorphisms at positions –1082 (G/A) 
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(rs1800896), −819 (T/C) (rs1800871), and −592 (A/C) (rs1800872) being 
associated with the transcription and production of IL-10 (Liu et al., 2010). In 
light of the established link between inflammation and MDD, it has been 
hypothesised that MDD patients may be carriers of a ‘low-producer’ 
polymorphism of the IL10 gene. The A/A genotype of the polymorphism at -
1082 has subsequently been identified as a ‘low-producer’ allele, and the 
distribution of this genotype has indeed been found to be significantly more 
prevalent in MDD patients than controls (Clerici et al., 2009). Furthermore, 
baseline peripheral levels of IL-10 (Clerici et al., 2009) have been demonstrated 
to be lower in MDD patients compared with controls. 
 
1.5.1.1.4 Tumour Necrosis Factor 
 
The TNF gene is located within the class III coding region of the major 
histocompatibility complex on the small arm of chromosome 6 (6p21.1–21.3; 
Clerici et al., 2009). The A-allele of rs1800629 [-308(G/A)], present in the 
promoter of the TNF gene, has been associated with MDD in a Korean 
population (Jun et al., 2003). In contrast to this finding, studies in a geriatric 
Caucasian population linked the G-allele to an increased risk of MDD (Cerri et 
al., 2009; Cerri et al., 2010). A large candidate gene association study of 1738 
MDD patients and 1802 controls polymorphism identified another SNP rs76917 
associated with MDD, with those carrying the T-allele being more likely to be 
cases (Bosker et al., 2011).  
In contrast to the somewhat mixed results at the genetic level, studies have 
fairly consistently reported higher levels of TNF mRNA and protein in the blood 
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of MDD patients relative to controls (Tsao et al., 2006; Cattaneo et al., 2012; 
Lanquillon et al., 2000; Tuglu et al., 2003; Raison et al., 2006; Yang et al., 2007; 
Schmidt et al., 2011; Savitz et al., 2012; Dowlati et al., 2010; Liu et al., 2012). 
Consequently, it may be that molecular influences at the epigenetic or 
transcription factor binding level relating to the pathophysiology of MDD make 
TNF mRNA and protein levels better predictors of MDD status than genotype 
alone. 
 
1.5.1.2 Cytokine biomarkers for treatment response 
 
Studies have revealed that molecular differences within the inflammatory 
cytokines may be useful in predicting how well patients will respond to 
antidepressant treatment. Specifically, the cytokines interleukin-6, tumour 
necrosis factor, interleukin-1B and interleukin-11 have been found to predict 




A major SNP in the IL6 gene (rs7801617) has been associated with a poor 
response to the SSRI escitalopram as part of a candidate gene association study 
(Uher et al., 2010). IL-6 has been shown to have the potential to switch the 
production of the neurotransmitter serotonin to acetylcholine in raphe neurons 
(Rudge et al., 1996). This inhibition of serotonin production by IL-6 could offer 
a possible explanation as to why IL6 genetic variants affect clinical response to 
SSRIs, which target the serotonin system. There have been few transcriptomic 
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studies investigating the links between IL6 transcription and treatment response, 
but those that have been performed have failed to show an association (Cattaneo 
et al., 2012). However, patients who are non-responders to antidepressants 
reportedly have increased plasma levels of IL6 (Maes et al., 1997; Lanquillon et 
al., 2000; Raison et al., 2006; Eller et al., 2008).  
 
1.5.1.2.2 Tumour Necrosis Factor 
 
Despite the associations between genetic variants within TNF and MDD 
[described in Section 1.5.1.1.4.], there have been no reports of genetic variants 
in TNF predicting response to antidepressants. In contrast, studies have reported 
that higher transcription and protein levels of TNF predict non-responsiveness 
to antidepressants (Cattaneo et al., 2012; Lanquillon et al., 2000; Tuglu et al., 
2003; Eller et al., 2008). For instance, higher baseline TNF protein levels have 
been found to predict a poor response to both tricyclics (Lanquillon et al., 2000) 
and SSRIs (Tuglu et al., 2003; Eller et al., 2008).  
There are four lines of evidence which support the potential role of TNF 
in moderating antidepressant response. Firstly. TNF is involved in the 
expression and functionality of the serotonin transporter, which is the primary 
pharmacological target of SSRIs (Mossner et al., 1998; Zhu et al., 2006). 
Consequently, TNF may moderate how antidepressants interact with the 
serotonin transporter and subsequently affecting response. Secondly, TNF has 
also been linked to induction of the indoleamine 2,3-dioxygenase (IDO) enzyme 
which breaks down the precursor to serotonin (Miller et al., 2009). Thus, 
increased production of TNF may lead to decreased serotonin synthesis, again 
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moderating the actions of antidepressants (Miller et al., 2009). Thirdly, TNF has 
also been demonstrated to inhibit hippocampal neurogenesis, which is a further 
mechanism by which antidepressants are thought to exert their therapeutic 
effects (Monje et al., 2003; Iosif et al., 2003). Finally, the TNF antagonist 
infliximab has recently been found to increase responsiveness to antidepressants 
in those with highest levels of inflammatory markers (Raison et al., 2013).  




The role of IL1B polymorphisms as putative diagnostic biomarkers for MDD 
has been discussed in Section 1.5.1.1.1. However, there is further evidence to 
show that SNPs with diagnostic properties may also predict treatment response 
to antidepressants. For example, those homozygous for the C-allele in -511C/T 
(rs16944) show a less favourable response to the SSRI fluoxetine than T-allele 
carriers, in a Chinese population (Yu et al., 2003). In contrast, carriers of the -
511T/T variant were associated with significantly faster and more pronounced 
response to the SSRI paroxetine than carriers of the -511C/C allele in a 
Caucasian population (Tadić et al., 2008). Whereas, there has been no 
association between -511C/T and response to the noradrenergic and specific 
serotonergic antidepressant mirtazapine (Tadić et al., 2008).  
Further IL1B polymorphisms associated with responsiveness to 
treatment include rs114643 in intron 6 and rs16944 in the promoter region. The 
G/G genotypes of both of these alleles were found to be significantly associated 
with non-remission after 6 weeks of antidepressant mono- or poly-therapy with 
! 48 
several antidepressant classes (Baune et al., 2010). However, further analysis of 
the G/G genotype versus AG/AA groups combined resulted in only rs1143643 
polymorphisms being associated with non-remission (Baune et al., 2010).  
Only one transcriptomic study in blood has revealed higher levels of IL1B 
mRNA predicting non-responsiveness to antidepressants (Cattaneo et al., 2012). 
Subsequently, there is a potential use of both genotype and transcriptomic 
biomarkers within IL-1B as predictors of antidepressant response, but it further 




The Intereukin-11 gene (IL11) is located on chromosome 19, consisting of five 
exons and four introns (McKinley et al., 1992). A SNP in IL11 was shown to be 
the best predictive marker of clinical response to escitalopram as part of a 
genome-wide association study (Uher et al., 2010). Carriers of the A allele in 
rs1126757 (A/A or A/G) in IL11 responded better to the SSRI escitalopram, 
than individuals homozygous for the G allele after 12 weeks of treatment (Uher 
et al., 2010). IL-11 is a close functional homologue of IL-6, and both of these 
cytokines are implicated in the inhibition of serotonin production from raphe 
neurons in the brain stem (see above). This inhibition of serotonin production 
could offer a possible explanation as to why variants in these genes may affect 
clinical response to SSRIs. Studies with larger sample sizes and multiple drugs 
are required to further establish the clinical implications of these SNPs. 
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1.5.1.3 Antidepressant-induced transcriptional changes and  
treatment-emergent biomarkers for antidepressant 
response 
As discussed in Section 1.5., the dynamic nature of transcription and protein 
expression suggests that these biochemical measures may also be used to 
monitor phenotypic change. Previous reports have revealed changes in the 
mRNA or protein levels of IL1B, IL6, macrophage migration inhibitory factor 
(MIF), TNF and IL-10 in response to antidepressant treatment (Lanquillon et 
al., 2000; Tuglu et al., 2003; Cattaneo et al., 2012). Furthermore, in one study, 
the magnitude of transcriptional changes in IL6 after 8 weeks of treatment with 
antidepressants predicted the magnitude of clinical response after 12 weeks of 
treatment (Cattaneo et al., 2012). Consequently, transcriptional and proteomic 
changes to cytokines during antidepressant treatment may be important in 
mediating antidepressant response. Furthermore, early changes in transcription 




Despite twin studies suggesting MDD is heritable, research has largely failed to 
identify specific genes associated with MDD. It has been suggested that gene-
environment interactions may contribute to the observed ‘missing heritability’, 
with eSLEs perhaps playing a particularly pertinent role in moderating 
susceptibility to MDD. The long-lasting genome-wide effects of eSLEs however 
remain unclear, and no GWASs have currently attempted to investigate gene-
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environment interactions on a genome-wide scale, which means few novel 
susceptibility loci have been identified for MDD in response to eSLEs. The 
search for biomarkers remains a key goal to improve diagnosis and treatment 
selection for MDD. Evidence suggests that molecular differences in the 
inflammatory cytokines may act as useful biomarkers for MDD, and for the 





1. To identify novel gene-environment interactions which increase 
risk to MDD. Using a maternal separation protocol in two inbred strains of 
mice showing long lasting differences in stress-reactivity in response to separation, 
we will investigate strain by stress interactions occurring at the transcriptional level 
in the hypothalamus. We will then form a hypothesis-driven analysis to assess 
whether genetic polymorphisms in these gene(s) interact with the presence of 
childhood neglect to predict MDD status in a human clinical cohort.  
 
2. To establish whether transcriptional biomarkers in the 
inflammatory cytokine pathway can differentiate between controls,  
MDD patients and bipolar disorder patients.  In Chapter 3 we will 
investigate whether transcriptional differences within the inflammatory cytokine 
pathway (using whole blood) can be used to differentiate MDD, bipolar disorder 
patients and controls. This is in an attempt to identify disorder-specific 
biomarkers which may reduce clinical misdiagnosis, a problem discussed in 
Section 1.4. 
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3. To establish whether transcriptional and epigenetic biomarkers 
in the inflammatory cytokine pathway can be used as predictors of 
cl inical antidepressant response. In chapter 4 we attempt to identify 
transcriptional predictors of antidepressant response in the inflammatory 
cytokine pathway in hopes of tackling the clinical problem of ineffective 
treatment, discusses in Section 1.4. Based on these results, we select further 
genes of interest to investigate at the DNA methylation level, in an attempt to 
identify epigenetic predictors of antidepressant response. 
 
4. To investigate whether antidepressant- induced transcriptional 
changes in the inflammatory cytokine pathway correspond to 
cl inical response. Finally, chapter 5 investigates the effects of an 
antidepressant on the transcription of cytokine genes and establishes whether 
molecular changes relate to clinical antidepressant response. Results from this 
study aims to identify potential molecular targets which may be important in 
moderating antidepressant efficacy, and aims to identify potential treatment-












interactions for major depressive 
disorder based on whole genome 
transcriptomic changes in mouse 


















Figure 2.0: Photographs of DBA/2J (top) and C57BL/6J (bottom) inbred mouse 




MDD is a heterogeneous disorder with numerous putative aetiological pathways 
and environmental and genetic risk factors (Lesch, 2004). Early stressful life 
events (eSLEs), such as childhood neglect and abuse, represent one 
environmental risk factor known to increase an individual’s susceptibility to 
MDD (Kaufman et al., 2001). Studies on rodent models have also shown that 
early separation of pups from their mothers, likened to childhood neglect in 
humans, alters the epigenome, the transcriptome, neurobiological circuitry and 
corticosterone reactivity, resulting in long-lasting physiological, and behavioural 
changes thought to parallel those found amongst MDD patients (Meaney, 2001; 
Kember et al, 2012).  
 Although eSLEs increase risk for MDD in some individuals, they do not 
increase risk for MDD in everyone. One attractive theory to explain this inter-
individual variability in MDD risk on exposure to eSLEs is that MDD may result 
from the interaction between genetic susceptibility loci and eSLEs (Keers et al., 
2011). For instance, both childhood neglect and abuse have been found to 
increase an individual’s susceptibility for MDD in later life, but these events also 
show interactions with previously identified susceptibility loci for MDD, such as 
5-HTTLPR, to moderate risk for MDD (Uher et al., 2011, Fisher et al., 2013). 
Based on the promising results from candidate gene-environment interaction 
studies [see Section 1.1.6 for more information], there is now an urgent need to 
explore whether other susceptibility loci across the genome may exist which 
interact with specific eSLEs to predispose to MDD.  
 The largest genome-wide association study for MDD to-date, however, 
has arguably been underpowered and was unable to identify novel genes robustly 
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associated with MDD (Major Depressive Disorder Working Group of the 
Psychiatric GWAS Consortium, 2013). It has subsequently been argued that 
even greater power will be required to detect gene-environment interactions on a 
genome-wide scale, after the burden of multiple testing correction (Duncan & 
Keller, 2011). Consequently, despite the promising findings detailed in candidate 
gene-environment interaction studies, progress in the field is limited and 
genome-wide studies remain a key goal for the future. 
 One way of prioritizing the investigation of novel MDD susceptibility loci 
in humans in a hypothesis-free manner stems from the utilization of animal 
models. For instance, a study by Malki et al. (2010) exploring the moderating 
effects of genetic variants on antidepressant response in a human clinical cohort, 
prioritized their investigation by selecting genes showing differential expression 
changes in the mouse brain in response to antidepressant treatment. 
Subsequently, similar methods could be employed to identify susceptibility loci 
for MDD in humans, by prioritizing genes which show expression changes in the 
mouse brain in response to eSLEs.  
 A recent study by our group, exploring the effect of an eSLE in two 
genetically distinct inbred mouse strains, revealed strain-specific molecular, 
behavioural, and hormonal changes in response to maternal separation (Kember 
et al., 2012). Of particular significance was the identification of a strain-specific 
exacerbation in stress reactivity in adult mice that had undergone a maternal 
separation; with C57BL/6J but not DBA/2J mice showing increased 
corticosterone release on exposure to a later life stressor (Kember et al., 2012). 
Elevated corticosterone reactivity and alterations to the hypothalamic-pituitary-
adrenal (HPA) axis are among the most reliable physiological biomarkers for 
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MDD to-date (Hellhammera et al., 2009). Consequently, these inbred strains 
may be modelling the effects of eSLEs in eSLE/MDD-vulnerable (C57BL/6J) 
individuals and eSLE/MDD-resistant (DBA/2J) individuals. Thus, examining 
strain-specific molecular differences in response to separation may provide an 
insight into how eSLEs increase susceptibility to MDD in humans. 
 In the current study we investigate strain by stress (separation) interactions 
at the level of the transcriptome, which represents a functional molecular output 
of gene-environment interactions. We measure gene expression in the 
hypothalamus (the control centre of the HPA-axis and stress response) in 
C57BL/6J and DBA/2J inbred mouse strains, and attempt to identify transcripts 
showing differential expression changes in response to maternal separation. We 
then use this to prioritise the investigation of potentially novel susceptibility loci 
interacting with childhood neglect to predict MDD case/control status in a 






C57BL/6J and DBA/2J mice were bred in the Biological Services Unit at the 
Institute of Psychiatry, Kings College London using original stocks [respective 
stock numbers: 000664, 000671] purchased from The Jackson Laboratory (Bar 
Harbor, ME, USA). DBA/2J and C57BL/6J strains were selected as these 
represent members of a priority list based on the most well-characterized, 
commonly used strains for gene manipulation and crosses (Mouse Phenome 
Project, http://aretha.jax.org/pub-cgi/phenome/mpdcgi?rtn=docs/home). 
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 Mice were housed in standard cages measuring 30.5×13×11 cm, kept at 
an ambient temperature (21±2°C) and light (light/dark cycle with white lights on 
from 08:00 to 20:00). Food for breeders (Rat and Mouse No. 3 diet, Special Diet 
Services, Essex, UK), food for test mice (Rat and Mouse No. 1 diet) and tap 
water was available ad libitum. Sawdust (Litaspen premium) and nesting materials 
(Sizzlenest, Datsand, Manchester, U.K.) in each cage were changed once every 
two weeks, but never on the day before or the day of testing to minimize the 
disruptive effect of cage cleaning on behavior. At postnatal day one, litters were 
reduced to 6 pups to standardize litter sizes. All housing and experimental 
procedures were performed in compliance with the UK Home Office Animals 
Scientific Procedures Act 1986. 
 
2.2.2 Modelling childhood neglect 
 
To model childhood neglect, a maternal separation protocol was used. Males 
were paired with female breeders for 2 weeks and then removed. Litters of each 
strain were randomly allocated to control or maternal separation groups. For the 
litters in the maternal separation group, the mother was removed from the litter 
on postnatal day 9 for 24 hours and returned to the housing room, leaving the 
pups in a procedure room. The cages containing the litters were placed on a 
heating pad and kept in a procedure room in order to maximize separation from 
their mother. After 24 hours, the dam was returned to the litter and the cage 
returned to the housing room. Control group litters were not disturbed and 
remained in the housing room with their mothers until they were weaned. Mice 
were weaned aged 5 weeks and two pups within each litter were randomly 
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assigned to one of three groups; test-naïve adolescent group (culled at 5 weeks), 
test-naïve adults (culled at 14-15 weeks) and test adults (tested at 11-12 weeks, 
culled at 14-15 weeks). The groups of adult mice were transferred at 
approximately 9 weeks of age to a separate housing and test facility and pair 
housed with a same sex sibling. All mice were allowed to habituate for 2 weeks 
before being either culled or undergoing a battery of behavioural tests and then 
culled. Culling was carried out using cervical dislocation and the hypothalamus 
and hippocampi were dissected. For the gene expression experiments, only adult 
male mice were used and there was a total of 23 control mice (n=10 C57BL/6J, 
n=13 DBA/2J) and 19 separated mice (n=9 C57BL/6J, n=10 DBA/2J). In order 
to reduce any effects behavioural testing may have on gene expression, the 
majority of mice used in gene expression experiments were behaviourally naïve 
except for three of the DBA/2J mice, which was corrected for when dealing with 
batch effects.  
 
2.2.3 Whole Genome Transcriptomics 
 
2.2.3.1 Ribonucleic acid  
 
Ribonucleic acid (RNA) is a chain of ribonucleotides (Berg et al., 2002). RNA 
primarily consists of three subtypes: ribosomal RNA (rRNA), transfer RNA 
(tRNA) and messenger RNA (mRNA) (Berg et al., 2002). The relative 
differences in total RNA extracted from biological material experimentally is 
usually attributed to quantitative differences in mRNA levels, which represents 
the molecular measure of gene expression, and codes for the sequence of amino 
acids in a polypeptide (Cooper & Haussman, 2004).  
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RNA has a short half-life and degrades quickly as result of the actions of enzymes 
which break down RNA (RNAases). Consequently, extracted RNA must be kept 
at low temperatures to inhibit the actions of these enzymes, undergo as few 
freeze-thaw cycles as possible, and be checked for degradation prior to gene 
expression experiments (Holzmann et al., 2008). 
 
2.2.3.2 RNA Extraction 
 
The Qiagen AllPrep DNA/RNA kit (Crawley, UK) was used to extract RNA and 
DNA, using the manufacturer’s standard protocol. Briefly, hypothalami were 
homogenized using disposable microcentrifuge tube tissue grinders (Anachem, 
UK). Subsequently, the homogenised tissue was spun through porous columns 
which trap nucleic acids. Nucleic acids are then washed and eluted, culminating 
in separate purified DNA and RNA elutions (see Figure 2.1). 
 
2.2.3.3 RNA Quantification 
 
RNA was quantified and checked for purity using the Nanodrop ND100 
(Thermoscientific, Wilmington, Delaware, USA). The concentration of each 
RNA sample was assessed by determining the absorbance of ultra violet light at 
260nm in a spectrophotometer using a quartz cuvette. The ratio of 
spectrophotometer readings at 260nm and 280nm was also used to estimate the 
purity of RNA, with 260/280 ratios between 1.8 and 2.1 considered good purity, 
and free of protein contamination. All RNA samples in the current study were of 






Figure 2.1: Key steps involved in RNA and DNA extraction using the Qiagen 




2.2.3.4. RNA Quality 
 
As mentioned in Section 2.2.3.1, RNA has a short half-life and degrades quickly 
which can affect its suitability for use in gene expression experiments. 
Subsequently, it is necessary to assess whether extracted RNA samples all show 
relatively low levels of degradation. To assess RNA quality we used the Agilent 
2100 Bioanalyzer (Agilent Technologies, Berkshire, UK). This system utilises a 
multi-well chip in which 12 RNA samples can be included per run. Briefly, the 
procedure involves using an electric current to drive RNA intercalated with a 
fluorescent dye towards electrodes. A constant mass-to-charge ratio means that 
molecules are separated by size with smaller fragments migrating faster than 
larger, heavier fragments. Two very large rRNA molecules (18S and 28S) form 
two distinctive peaks on generated electropherograms (see Figure 2.2). The 
sharpness of the 18S and 28S peaks and the ratios between these peaks are 
incorporated along with other information to form a quantitative measure of 
RNA integrity, a RNA integrity Number or “RIN”. RNA samples generating 
RINs between 7 and 10 are usually considered good quality. All RNA samples 
used in this study had RINs of 8±1. 
 
2.2.3.5. Whole Genome Amplification 
100ng of extracted RNA was processed with the Ambion WT expression kit and 
underwent whole genome amplification using the standard manufacturer 
protocols. The amplification process consisted of 10 steps: (i) first strand cDNA 
synthesis, (ii) second strand cDNA synthesis, (iii) cRNA synthesis, (iv) cRNA 
purification, (v) assessment of cRNA yield and size distribution, (vi) synthesis of 
second cycle DNA, (vii) hydrolysis, (viii) purification of second cycle DNA, (xi) 
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assess cDNA yield and size distribution, (x) fragment and label the single-
stranded cDNA.  
 
 
Figure 2.2: An electropherogram trace for non-degraded RNA. Note the high 
and sharp florescent signals generated for M (marker), and 18S and 28S 
ribosomal RNA fragments. 
 
2.2.3.6. Affymetrix Gene Chip 1.0 ST arrays 
 
Affymetrix Gene Chip 1.0 ST arrays (Affymetrix, High Wycombe, UK) were 
used to measure genome-wide expression and contain probes covering all of the 
28,853 genes within the Mus musculus genome. Using the Affymetrix Gene Chip 
Hybridisation Kit, 5.5 ug of synthesized single-stranded cDNA was fragmented, 
labelled and then hybridized to the arrays. Arrays were then washed and stained 
and then scanned in the Affymetrix Gene Chip 3000 machine. AGCC scan 
control software was used to generate cel files.  
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2.2.3.7. Array Pre-processing and Normalisation 
 
Data normalisation was performed using the Robust Multiarray Average (RMA) 
package available at www.bioconductor.org for use in R (http://www.R-
project.org). Briefly, pre-processing of the array data using RMA involves three 
key steps: (i) RMA convolution; which implements background adjustment 
during which perfect match values are corrected array-by-array using a global 
model of the distribution of probe intensities; (ii) Quantile normalisation; this 
process impose the same empirical distribution of intensities to each array; (iii) 
Summarization; the process combines the multiple probe intensities for each 
probeset to produce an expression value (Irizarry et al., 2003). The final output is 
log-transformed RMA values signifying probe intensity summaries for each gene.  
 




Subjects with recurrent MDD and healthy controls were drawn from two sites 
within the UK, Cardiff and London, as part of the Depression Case–Control 
(DeCC) study (see Cohen- Woods et al., 2009). The DeCC study was approved 
by the local ethics committees at each site and all participants provided written 
informed consent. 
 All participants in DeCC were over the age of 18, and of White 
European parentage. Subjects were identified through psychiatric clinics, 
hospitals, general medical practitioner surgeries, and media advertisements. 
MDD patients must have experienced at least two major depressive episodes of 
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at least moderate severity and separated by two or more months of remission, as 
defined by DSM-IV (American Psychiatric Association, 2000) and/or ICD-10 
(World Health Organisation, 1993). Major depression diagnosis in recruited 
patients was confirmed at interview using the Schedules for Clinical Assessment 
in Neuropsychiatry (SCAN; Wing et al., 1990). Exclusion criteria were history of 
mania or hypomania, mood-incongruent psychosis, and a first or second- degree 
relative with bipolar or psychotic disorder. MDD patients were also excluded if 
their depression had only occurred secondary to physical illness, medication, or 
substance or alcohol misuse, if they were intravenous drug users with a lifetime 
diagnosis of dependency, or if they were related to an individual already included 
in the study group.  
 Control subjects were recruited through UK general medical practices 
and excluded if they had a personal or first-degree relative with a history of any 
psychiatric disorder. They were screened for lifetime absence of psychiatric 
disorders using a screening method adapted from the Past History Schedule 
(McGuffin et al., 1986). Control subjects were also excluded if they scored 10 or 
above on the Beck Depression Inventory (BDI) (Beck & Steer, 1984), or failed 
to return consent or cheek swabs. 
 
2.2.4.2. Measures of Early Life Stress 
 
Self-reported information on emotional abuse, physical abuse, sexual abuse, 
emotional neglect (EN) and physical neglect (PN) during childhood were 
captured using the Childhood Trauma Questionnaire (CTQ; Bernstein et al., 
2003). In total we had CTQ ratings for 197 recurrent MDD cases and 286 
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screened controls. For the purposes of this study we only utilise information 
related to neglect (i.e. EN and PN), as these measures relate more strongly to the 
maternal separation model in which the pup is both physically and emotionally 
absent from their mother. Subscale scores of the CTQ were coded as none (0), 
mild (1), moderate (2) and severe (3) in accordance with the manual (Bernstein 
et al., 2003). As in Fisher et al., (2013) moderate (2) and severe (3) categories for 
each maltreatment type were collapsed into one group due to the small numbers 
of participants in the ‘severe’ category in DeCC. 
 
2.2.4.3. Genome-wide genotyping 
 
Genomic DNA was extracted from bloods and cheek swabs collected as 
described previously (Freeman et al., 2003). DNA samples were then sent to the 
Centre National de Genotypage (Evry Cedex, France) and were genotyped using 
the Illumina Human610-Quad bead chip (Illumina, Inc., San Diego, CA, USA). 
Genotype data for single nucleotide polymorphisms (SNPs) under investigation 
in this study were extracted using PLINK (Purcell et al., 2007). 
 
2.2.5. Statistical Analysis 
 
Testing for significance in our expression data was achieved using a univariate 
linear regression, which incorporated main effects (strain, stress), nuisance factors 
(array batch effects) and our interaction effect (stress x strain interaction). The 
False Discovery Rate (FDR) method of multiple testing correction was applied, 
and q-values of q<0.1 were considered true discoveries. Ingenuity Pathway 
analysis was performed for all probes producing p-values of p<0.01 in order to 
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identify any gene networks affected as part of strain x stress interactions. For our 
top stress x strain interaction we further investigated this gene in our human 
cohort. We extracted SNPs 30KB upstream and 10KB downstream of the gene. 
The ‘genhw’ package in STATA 11.0 (StataCorp, Texas, USA) was used to 
assess whether genotype frequencies diverged from the Hardy-Weinberg 
Equilibrium. We then assessed whether either PN or EN showed an interaction 
with extracted SNPs to predict MDD status. The main effects of the SNP, the 
main effect of neglect (either EN/PN) and interactions between childhood 
neglect and the SNP, on the presence/absence of recurrent MDD was examined 
using a generalized linear models with a binomial distribution and identity link 
function specified (Wacholder, 1986), and was adjusted for the effects of gender, 
as in Fisher et al., 2013. For any SNP which generated a significant interaction in 
our model (p<0.05), we further tested whether one allele might be dominant in 
driving the interaction. We achieved this by dichotomizing genotypes into those 
carrying at least one copy of the major allele (1/0), and repeating our generalized 
linear model. We then dichotomized genotypes into those carrying at least one 
copy of the minor allele (1/0) and repeated the linear model. If one allele shows 
a stronger interaction with neglect, we assume this is the dominant allele driving 




2.6.1. Whole Genome Transcriptomics 
 
Univariate linear regressions revealed no significant stress x strain interactions at 
the transcriptomic level after multiple testing correction, i.e. all transcripts 
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generated q>0.1. The results from the top eight stress x strain interactions are 
given in Table 2.1 and graphically presented in Figure 2.3. The top interaction 
was found in the probe 10500345, which relates to the transcript telomerase 
RNA component (Terc). The top associated network based on pathway analysis 
was ‘Organ Morphology, Reproductive System Development and Function, 
Cardiac Arrythmia’, which also featured Terc, see Figure 2.4. Subsequent in 
silico analysis confirmed that there is a SNP downstream (<10KB) of the Terc 
gene (MRS1058401), which differs between C57BL/6J (GG carriers) and 
DBA/2J mice (TT carriers). 
 
 
Probe Identifier Gene Symbol Chromosome p-value 
10500345 Terc 3 1.70E-05 
10505879 Ifna7 9 1.75E-04 
10493494 Efna3 1 1.95E-04 
10414485 Olfr265 14 2.22E-04 
10498795 Zfp108 7 3.00E-04 
10551393 Akt2 10 4.64E-04 
10500103 Gabpb2 3 4.75E-04 
10508089 Mrps15 4 5.10E-04 
 
 
Table 2.1 Table displaying the eight most significant probes showing stress x 
strain interactions at the transcriptomic level in the hypothalamus, based on 
results from univariate linear regressions. Information listed includes the probe 
identifier on the Affymetrix Gene Chip 1.0 ST array, the corresponding gene, its 


















Figure 2.3: Strip charts showing the distribution of probe intensities (RMA 
values) for C57BL/6J mice shown on the left of each chart, and DBA/2J shown 
on the right of each chart. Results from controls are shown in black and results 
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Figure 2.4: Results from Ingenuity Pathway Analysis. Figure depicts genes 
involved in the “Organ Morphology, Reproductive System Development and 
Function, Cardiac Arrythmia” network which was the top gene network showing 
expression differences as part of a stress by strain interaction in the hypothalamus 
in response to maternal separation. Results were based on inputting 239 
transcripts which produced uncorrected p-values of p<0.01 from strain by stress 
analyses into Ingenuity Pathway Analysis. The transcript showing the most 
significant stress by strain interaction, Terc, is shown in darker red. 
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2.6.2. Human Genetic Association  
 
We extracted genotype information using PLINK (Purcell et al., 2007) for all 
SNPs located -30KB and +10KB of TERC (chr3:170,965,092-170,965,542; 
Genome Reference Consortium GRCh37/USCS version hg19). Three SNPs 
within this region were present on the genotyping platform with the following 
genotype frequencies: rs11718668 [CC (n=256), CT (n=189), TT (n=38)], 
rs1881984 [AA (n=230), AG (n=204), GG (n=49)], rs10936599 [CC (n=294); CT 
(n=158); TT (n=31)]. None of the genotypes deviated from Hardy-Weinberg 
equilibrium. Results revealed that the SNP furthest downstream, rs10936599, 
significantly interacted with severity of emotional neglect to predict MDD status, 
see Table 2.2. rs10936599 consists of a major allele C, and minor allele T. We 
found the dominant effect to be on the C-allele, with those carrying at least one 
copy of the C-allele showing strongest interactions with emotional neglect to 
predict MDD status [R.D. =-0.063; 95% C.I. = 0.017 - 0.108; p = 0.007], rather 
than those carrying at least one copy of the T-allele [R.D. = 0.061; 95% C.I. = -











Interaction RD 95% CI p 
rs11718668 x EN 0.015 -0.060 0.091 0.690 
rs10936599 x EN 0.078 -0.149 0.007 0.029* 
rs1881984 x EN 0.039 -0.032 0.111 0.280 
rs11718668 x PN -0.001 -0.077 0.075 0.986 
rs10936599 x PN 0.037 -0.022 0.095 0.218 
rs1881984 x PN 0.011 -0.060 0.082 0.767 
 
 
Table 2.2 Results from linear regressions investigating whether interactions 
existed between each of our three SNPs (rs11718668, rs10936599, rs1881984) 
and either emotional neglect (EN) or physical neglect (PN) to predict MDD 
case/control status. Results detailed include risk difference (RD), 95% confidence 
intervals (95% CI) and p-values (p). Significant interactions (p<0.05) are 




Gene-environment interactions represent a potentially important mechanism 
through which eSLEs increase some individuals’ susceptibility to MDD (Nugent 
et al., 2011). Currently, insufficient power is available to detect novel gene-
environment interactions for MDD on a genome-wide scale, however methods 
can be employed to narrow down the search (Duncan & Keller, 2011; Malki et 
al., 2010). The current study utilised a maternal separation procedure in two 
inbred strains of mice, which exhibit different stress-reactivity profiles in 
adulthood in response to separation (see Kember et al., 2012). The project 
aimed to model childhood neglect and investigate whether stress by strain 
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interactions present at the level of the transcriptome could be used to prioritise 
the search for gene-environment interactions for MDD in humans.  
 Our study revealed no stress by strain interactions which remained 
significant after multiple testing correction (see Table 2.1). However, our top 
interaction was found in the transcript telomerase RNA component (Terc) (see 
Table 2.1 and Figure 2.3), which is also featured in our top gene network (see 
Figure 2.4). Terc codes for the RNA component of the telomerase enzyme, 
which is a ribonucleoprotein polymerase that maintains telomere ends (Marrone 
& Dokal, 2007). Specifically, Terc provides the template for creating the 
repeated sequence of DNA, TTAGGG, that telomerase adds to the ends of 
chromosomes (Shalev, 2012). Telomere shortening has been associated with 
aging and increased numbers of cell divisions, and mutations in the TERC gene 
have previously been associated with the aging-like disease dyskeratosis 
congenital (Vulliamy et al., 2011). Recent research has also reported shorter 
telomeres amongst adults who have experienced emotional and physical neglect 
in childhood (Tyrka et al., 2010), adults who have experienced childhood trauma 
(O'Donovan et al., 2011), and in children who have experienced domestic 
violence (Shalev et al., 2013). Furthermore, shorter telomeres have been 
reported amongst patients with psychiatric disorders, and particularly amongst 
patients with mood disorders (Simon et al., 2006; Hartmann et al., 2010; 
Elvsashagen et al., 2011; Wikgren et al., 2012).   
 There are numerous theories about the processes which may be involved 
in accelerated telomere shortening or ‘telomere erosion’ in response to eSLEs, 
such as neglect. Theories include immune and endocrine activation, oxidative 
stress and mitochondrial dysfunction (Shalev, 2012). However, most current 
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theories converge around the idea that a disturbed HPA axis and heightened 
cortisol levels, are linked to greater ‘cellular aging’ and telomere erosion 
(Wickgren et al., 2012). In this study, we provide the first evidence that an eSLE, 
provoking strain-specific alterations in HPA-reactivity, is associated with 
differential transcriptional rates for the telomerase coding gene Terc in the 
hypothalamus. Alterations to the expression of Terc in response to stress 
provides a potential mechanism through which eSLEs evoke enduring alterations 
to telomere length. 
 Based on these findings, we further tested whether SNPs within TERC 
(or 30KB upstream/10KB downstream of TERC) interacted with severity of 
physical or emotional neglect (human phenotypes most closely analogous to 
maternal separation) to predict MDD status in a human clinical MDD case-
control cohort. Results revealed that a SNP downstream of TERC, rs10936599, 
located in the exon of a neighbouring gene coding for a BTB/POZ and zinc 
finger transcription factor, myoneurin (MYNN), interacted specifically with 
severity of emotional neglect to predict MDD case/control status. The presence 
of at least one copy of the major C-allele was found to most strongly interact with 
emotional neglect to predict MDD case/control status. Interestingly, rs10936599 
has been identified as the strongest genetic predictor of telomere length as part of 
a recent GWAS (Codd et al., 2013), with the major C-allele being associated with 
longer telomeres, relative to the minor T-allele (Jones et al., 2012). rs10936599 is 
also in strong linkage disequilibrium (LD) with a known functional SNP within 
the TERC gene, rs2293607, known to affect TERC mRNA expression and 
telomere length (Jones et al., 2012). Consequently, our results may suggest that 
those with a genetic predisposition to longer telomeres (C-allele carriers) are 
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particularly vulnerable to the effects of childhood neglect. However, the exact 
mechanisms through which TERC expression and telomere length might impact 
upon the pathophysiology of MDD remains unclear.  
 Despite the promising results detailed here, there are numerous 
limitations to the current study. Firstly, the animal component of the study 
utilised a small number of mice, and we were unable to detect any significant 
strain by stress interactions after multiple testing correction. Therefore, the 
effects neglect may have on the expression of TERC in the mouse brain need to 
be replicated in a larger sample to confirm it is a true effect. Secondly, we liken 
maternal separation in this study to childhood neglect because it involves the 
absence of physical and emotional support from the primary carer during early 
life. However, this interpretation is likely over-simplified. The maternal 
separation procedure employed here models an acute form of ‘neglect’, whereas 
human childhood neglect is probably more chronic in nature, occurring on 
repeated occasions, with differing severities. Consequently, a single separation 
protocol may not accurately model the complexities associated with childhood 
neglect. Thirdly, measures of telomerase activity and telomere length would be 
beneficial to confirm that the observed differences in TERC expression 
correspond to functional differences in enzyme activity and telomere length. 
Furthermore, the animal component of the study observes the effects of 
separation cross-sectionally, and the human component assesses neglect 
retrospectively. A future study design should investigate the effects of separation 
in mouse in a longitudinal manner and observe whether cumulative later life 
stressors further have an effect on Terc expression and telomere length in the 
hypothalamus. Similarly, longitudinal studies collecting information about eSLEs 
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(e.g. as reported in Shalev et al., 2013) may limit the effects of any retrospective 
reporting bias present in this study. Additionally, our human sample is still 
relatively small and the interaction between rs10936599 and emotional neglect 
requires replication. Finally, it would be useful to test whether rs10936599 or 
rs2293607 (SNP in LD with rs10936599) interacts with childhood neglect in 
humans to differentially predict TERC expression levels and telomere length.  
 In conclusion, our results are the first to reveal potentially important 
interactions between different genetic backgrounds and early neglect on the 
expression of the telomerase gene Terc. Furthermore, a SNP (rs10936599) 
downstream of TERC previously found as the strongest genetic predictor of 
telomere length, significantly interacted with severity of early emotional neglect to 
predict MDD status in a human clinical case-control cohort. If replicated, this 
could provide a potential aetiological pathway between childhood neglect and 
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The term ‘mood disorder’ refers to a category of psychiatric illnesses that are 
characterized by a pathological distortion of emotional mood (Jones et al., 2002). 
Mood disorders represent the most common form of severe adult-onset 
psychiatric disorder and are predicted to be the second most common cause of 
morbidity by 2020 (Craddock & Forty, 2006; Murray & Lopez, 1996). They 
consist of two aetiologically related (McGuffin et al., 2003) but distinctly treated 
psychiatric illnesses (Nemeroff & Owens, 2002), MDD and bipolar disorder 
(BPD). Both MDD and BPD are clinically characterized by episodes of 
depression (e.g. lowered mood, loss of interest or pleasure, loss of energy); with 
BPD also consisting of episodes of mania or hypomania (e.g. expanded self-
esteem, increased distractibility, talkativeness; World Health Organisation, 1992; 
American Psychiatric Association, 2000).  
Despite the establishment of clinical diagnostic criteria for MDD and 
BPD, the heterogeneous nature of these disorders, the similarities they share in 
their clinical presentation, and the absence of specific biomarkers, means there 
are relatively high rates of misdiagnosis (Kendell, 1976; Farmer & McGuffin, 
1989). BPD is often misdiagnosed in the first instance (Hirschfeld et al., 2003), 
and an estimated 5.7 years on average is required for the correct diagnosis 
(Morselli & Elgie, 2003). Most frequently, BPD is misdiagnosed as MDD due to 
their overlapping symptomology, the often later onset of mania, and more 
frequent occurrence of depressive episodes in BPD patients (Lewis et al., 2003; 
Perlis, 2005). Misdiagnosis may be particularly high when BPD patients present 
symptoms indicative of a clinically significant depressive episode but are 
premorbid for manic symptoms, or have failed to recognize previous manic 
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states. Misdiagnosis, and therefore incorrect treatment of BPD with 
monotherapy antidepressant treatment, increases the risk of antidepressant 
induced mania (Wehr & Goodwin, 1979; Altshuler, et al., 1995) and “cycle 
acceleration” (an increased frequency of episodes) (Perlis, 2005); both of which 
can have damaging effects on disease prognosis. Consequently, the establishment 
of biomarkers specific to each disorder remains a key goal, so that the correct 
diagnosis and treatment can be obtained for a patient from the outset.  
 The clear need for an objective, empirical method of diagnosis has led to 
genome-wide association studies (GWASs) attempting to identify genes 
associated with MDD and BPD. However, despite twin studies suggesting mood 
disorders are moderately heritable, GWASs have largely been unsuccessful in 
identifying genes robustly associated with MDD (McGuffin et al., 2003; Major 
Depressive Disorder Working Group of the Psychiatric GWAS Consortium, 
2012), with only recent reports from very large-scale studies finding genes 
potentially being associated with BPD (Psychiatric GWAS Consortium Bipolar 
Disorder Working Group, 2011). In addition to genetic background, it has been 
established that environmental factors, such as stressful life events, can also 
increase a person’s susceptibility to developing a mood disorder, and precipitate 
mood disorder episodes (Kendler et al., 1999; Hosang et al., 2012). 
Subsequently, it has been proposed that a lack of findings from GWASs might 
relate to the more salient presence of gene-environment interactions (Keers & 
Uher, 2012), as supported by studies in the field (e.g. Caspi et al., 2003; Kim et 
al., 2007; Bradley et al., 2008; Fisher et al., 2013; see Section 1.1.6 ). Therefore, 
it may be the interface between genes and environment that contains the most 
valuable biomarker information about mood disorders, as opposed to genotype 
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alone. Thus, focusing efforts on identifying biomarkers at the level of the 
transcriptome, which represents the functional molecular output of gene-
environment interactions, might yield more fruitful results.  
 Cytokines are a group of cell-signaling molecules which, in the periphery, 
aid inflammatory processes and the immune system to form co-ordinated 
responses to infection (Dantzer et al., 2008). Cytokines are also expressed 
centrally and have effects on the brain, influencing neurotransmitter systems, 
neuroendocrine function and neural plasticity, and converging evidence suggests 
they may play an important role in the pathophysiology of mood disorders 
(Miller et al., 2009). Furthermore, cytokines can cross the blood-brain barrier 
(Banks et al., 1995), so peripheral cytokines may represent a potentially useful 
biomarker resource relating to mood disorders. Indeed, both protein and 
transcriptomic studies performed in blood have revealed differences in the 
expression of cytokines such as interleukin-6, tumor necrosis factor and 
interleukin-1β amongst MDD patients relative to controls (Tsao et al., 2006; 
Cattaneo et al., 2012; Hiles et al., 2012; Liu et al., 2012). Similarly, the 
transcription of cytokines has been found to differentiate between BPD patients 
and controls (Padmos et al., 2008). However, no studies have yet investigated 
whether disorder-specific transcriptional differences exist within the inflammatory 
cytokine pathway, or whether this could be harnessed as clinical diagnostic aids 
to differentiate between MDD and BPD patients. 
 The current study aims to identify transcriptomic biomarkers in the 
inflammatory cytokine pathway which could be used to distinguish between 
controls subjects, MDD patients and BPD patients. We achieve this using RNA 
extracted from whole blood and examine an extensive set of inflammatory-
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related transcripts including genes coding for: interleukins and interleukin 
receptors, chemokines and chemokine receptors, the tumour necrosis factor 
cytokine family and receptors, and other inflammatory regulators. We initially 
test for differences in a discovery cohort (total n=90), and then attempt to 
replicate any findings from our discovery cohort in a pseudo-independent 




3.2.1 Clinical Samples 
Patient samples used in this study were collected from two methodologically 
similar studies, the Bipolar Association Case–Control Study (BACCS) (Cohen-
Woods et al., 2010) and the Genome-based Therapeutic Drugs for Depression 
Project (GENDEP) (Uher et al., 2010). 
 
3.2.1.1 Bipolar Disorder Patients  
BPD patients in BACCS were recruited from three sites, Toronto Canada, 
London UK and Dundee UK. BACCS was a community-based study, where 
subjects were recruited from psychiatric clinics, hospitals, primary care physicians 
and patient support groups. BPD patients were included in the study if they were 
over the age of 18 and had been diagnosed with Bipolar I or Bipolar II disorder 
as defined by the DSM-IV or ICD-10 (World Health Organisation, 1992; 
American Psychiatric Association, 2000). All patients were interviewed using the 
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Schedules for Clinical Assessment in Neuropsychiatry (SCAN) (Wing et al., 
1998).  All patients recruited in BACCS were euthymic (not in a clinically 
significant mood episode) at the time of interview and blood collection. All 
subjects were of White European parentage. Exclusion criteria include: first-
degree relative having fulfilled criteria for schizophrenia; psychotic symptoms 
that were mood incongruent or present when there was no evidence for mood 
disturbance; intravenous drug use with a lifetime diagnosis of drug dependency; 
mania or depression occurring solely in relation to, or a consequence of, alcohol 
or substance abuse/dependence and/or medical illness; being related to an 
individual already included in the study. The BACC study was approved by 
ethics boards of participating centres and all patients provided written informed 
consent. 
The current study utilized 40 BPD patient samples in total (30 in the 
discovery cohort and 10 in the replication cohort) collected only from the 
Dundee UK site, as this was the only site to collect blood for transcriptomic 
experiments. The subset used here was randomly selected from a larger group of 
samples. Further patient characteristics are detailed in Tables 3.1 and 3.2. 
 
3.2.1.2 Major Depressive Disorder Patients 
MDD patient samples were collected as part of the European study GENDEP, 
which is a 12-week partially randomized open label pharmacogenetic study. 
Patients were selected if they were diagnosed with MDD of at least moderate 
severity according to ICD-10 or DSM-IV criteria (World Health Organisation, 
1992; American Psychiatric Association, 2000). Patients in GENDEP were aged 
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between 19–72 years and of White European parentage. Diagnoses were 
established using the semistructured SCAN interview (Wing et al., 1998). 
Exclusion criteria included personal and family history of schizophrenia or 
bipolar disorder; current substance dependence; being related to an individual 
already included in the study; known treatment resistance to both of the 
antidepressants given as part of the study. Patients with no contraindications were 
randomly allocated to flexible-dosage nortriptyline (50–150mg daily) or 
escitalopram (10–30 mg daily) for 12 weeks. Patients with contra-indications for 
one drug were offered the other. Blood was collected both at baseline and after 
eight weeks of treatment, which allows the study to draw comparisons from other 
clinical drug trials and pharmacogenetic studies using similar drug treatment 
durations. The GENDEP study was approved by ethics boards of participating 
centres, and all participants provided written informed consent.  
The current study utilizes 46 patients in total (randomized to 30 in the 
discovery cohort and 16 in the replication cohort). The subset was selected and 
utilized for use in our previous studies (see Powell et al., 2012, 2013; see Chapter 
4 and 6). Blood samples were collected both at the start of GENDEP and after 
eight weeks of treatment with escitalopram. All patients completed the Beck 
Depression Inventory at the time of blood collection (BDI; Beck & Steer, 1984). 
We utilised blood collected after eight weeks of treatment with escitalopram, for 
both our discovery and validation cohorts, and we did so for two reasons. Firstly, 
we have previously shown in this sample that escitalopram has no significant 
effect on the transcription of genes in the inflammatory cytokine pathway with the 
exception of ATP-binding cassette sub-family F member 1 (see Powell et al., 
2013; Chapter 6), which will be excluded as a potential biomarker. Therefore, 
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medication is unlikely to act as a confounding factor in this sample. Secondly, we 
chose this time point, as it allowed us to adjust for the possible confounding 
effects of current mood state. Unlike the start of the GENDEP trial where all 
patient were in a clinically significant depressed state, after eight weeks of 
treatment, 26 patients still showed mild to moderate depression (defined here by 
BDI>10), whereas 20 patients were no longer in a clinically significant depressed 
state (defined here by BDI≤10). This allowed us to adjust our data for the effects 
of current mood state and draw comparisons with controls and BPD patients 
who were not in a clinically significant mood state at the time of blood collection. 
Further patient characteristics are shown in Tables 3.1 and 3.2. 
We also utilised blood which was collected at the start of GENDEP to 
ascertain how stable transcriptional biomarkers were at differentiating MDD 
patients from other subject groups. At the start of GENDEP all patients had 
been drug-free for two weeks and were all in a clinically significant mood state 
(BDI>10).  We assessed whether identified transcripts which were replicated in 
the validation cohort, continue to differentiate MDD patients from other subjects 
when blood is collected at a different time point, during different mood states, 
and during the absence of medication.  
 
3.2.1.3 Control Subjects 
Control subjects were selected from the Dundee, UK site, as part of BACCS. 
Control subjects were screened for lifetime absence of psychiatric disorder using 
a modified version of the Past History Schedule (McGuffin et al., 1986). All 
controls subjects were of white European parentage. Exclusion criteria were if 
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they; or a first-degree relative, ever fulfilled criteria for BPD, MDD or any other 
psychiatric disorder; if they had a BDI score of greater than 10 (Beck & Steer, 
1984); did not return consent; failed to return cheek swabs or successfully give 
blood. The current study utilised 40 subject blood samples in total (30 in 
discovery cohort and 10 in replication cohort). Further subject characteristics are 
shown in Tables 3.1 and 3.2. 
 
3.2.2 Experimental details 
 
3.2.2.1 RNA Extraction 
All blood samples from BACCS and GENDEP were collected in 10 ml 
PAXgene tubes (PreAnalytiX, Switzerland) and stored at -80°C. Prior to the start 
of gene expression studies, PAXgene tubes were allowed to thaw for 12 hours at 
room temperature. RNA extraction was performed using the Qiagen PAXgene 
Blood miRNA Kit (PreAnalytiX) following the standard manufacturer’s protocol, 
see Figure 3.1 for a summary of the extraction procedure. The purity and 
quantity of RNA was measured using the Nanodrop, ND1000 (Thermoscientific, 
Wilmington, DE). All samples had 260/280 ratios of between 1.9 and 2.3 [see 
Section 2.2.3.3 for more information]. RNA integrity numbers (RINs) were 
furthermore assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies, 

































































































































Table 3.1: A summary of subject characteristics in our discovery cohort. This 
includes general characteristics (total number in each subject group, age, number 
of males, number of females), information about co-morbidity (body mass index 
(BMI), number with diabetes, number with cardiovascular problems), and 
medication history (recent use of antidepressants, antipsychotics, lithium, 


































































































































Table 3.2: A summary of subject characteristics in our validation cohort. This 
includes general characteristics (total number in each subject group, age, number 
of males, number of females), information about co-morbidity (body mass index 
(BMI), number with diabetes, number with cardiovascular problems), and 
medication history (recent use of antidepressants, antipsychotics, lithium, 




Figure 3.1: A summary of key steps involved in the extraction of RNA from 
whole blood stored in PAXgene tubes using the Qiagen PAXgene Blood 
miRNA Kit (PreAnalytiX).   
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3.2.2.2 Quantitative Polymerase Chain Reaction (qPCR) 
A polymerase chain reaction (PCR) is a reaction in which a target sequence 
within a gene of interest is amplified through the actions of a DNA polymerase 
enzyme. qPCR involves the addition of a fluorescent dye which intercalates with 
double-stranded DNA allowing the amplification process to be detected in  
 ‘real time’. The ‘cycle threshold’ (Ct) value, is the key measurement in qPCR 
and refers to the number of amplification cycles required for a particular gene to 
reach a user-defined threshold of fluorescent signal, set above the level of 
background fluorescence.  
The relative quantification method of normalization is often employed 
for qPCR data and requires the subtraction of relatively stable reference genes’ 
expression from the potentially more dynamic expression of the target gene 
(Livak & Schmittgen, 2001). This process allows for comparisons across different 
samples, as the reference genes used for normalization are subject to the same 
conditions as the target gene itself; for example RNA integrity, reverse 
transcription efficiency and amount of starting material. 
Reagents used in the qPCR component of the study were manufactured 
by SABiosciences (Frederick, MD, USA). Complementary DNA (cDNA) was 
prepared using 1 µg of total RNA and the SABiosciences RT2 HT First Strand 
Kit following the manufacturer’s protocol. Briefly, following genomic DNA 
removal, the samples were incubated for 15 minutes at 42°C with 6 µl of BC4 
RT Mastermix (SABiosciences). The reverse transcriptase enzyme was 
subsequently inactivated at 95°C for 5 minutes. cDNA samples generated were 
stored at -20°C prior to use in the qPCR experiments. 
Customized 384-well arrays were designed for qPCR experiments. These 
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arrays contained lyophilized primers for the 84 genes listed in the commercially 
available Human Inflammatory Cytokines & Receptors PCR Array 
(SABiosciences), with the addition of gene primers for interleukin-11 (IL11) and 
interleukin-6 (IL6) and the glucocorticoid receptor (NR3C1). Each array 
contained five housekeeping genes for normalization. These include: β2-
microglobulin (B2M), Hypoxanthine phosphoribosyltransferase (HPRT1), 
Ribosomal protein L13a (RPL13A), glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) and β-actin (ACTB). Previous work has found that different mood 
disorder pharmacotherapies can differentially affect the expression of house 
keeping genes, impinging upon their usefulness as normalisation factors (see 
Powell et al., in press as provided in Appendix B). Thus, the three most stable 
housekeeping genes were selected based on RefFinder analyses and used for 
normalisation across samples.  
Each 384-well array was designed to analyze four samples simultaneously. 
The qPCR reagents used consisted of: 550 µl of 2X SABiosciences RT2 qPCR 
Master Mix (SYBR green), 102 µl of diluted synthesized cDNA and 448 µl 
RNAse free water, with a total volume of 1100 µl for each sample. 10 µl was then 
added to each well on the array. Each qPCR array contained the following 
controls: human genomic DNA control (gDNA), reverse transcription control 
(RTC) and a positive PCR control (PPC). To ascertain whether samples passed 
quality control checks for gDNA and RTC, the manufacturer’s quality control 
criteria were applied. The qPCR reactions were performed using the ABI Prism 
7900HT Sequence Detection System (Applied Biosystems, California, USA). 
Thermal cycling conditions consisted of an enzyme activation stage (95 °C for 10 
minutes), followed by 40 cycles of a denaturation stage (95°C for 15 secs) and a 
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hybridization and extension stage (65°C for 1 minute). The software program 
SDS 2.3 (Applied Biosystems) generated cycle threshold values (Ct) from the 
data collected 
 
3.3 Statistical Analysis 
Generated Ct values of greater than 37 were removed and excluded from further 
analysis as such high Ct values are indicative of very low expression levels. 
Furthermore, if as a result of data removal, a gene showed missing data for more 
than half of the total patient sample, that gene was excluded from further 
analysis. The relative expression of target genes was calculated by subtracting the 
mean Ct of the selected reference genes from the Ct of the target gene to generate 
ΔCt values (Livak & Schmittgen, 2001).  The three most stable housekeeping 
genes were selected as reference genes for normalization purposes based on 
RefFinder analyses, which is available as a web-based tool 
(http://www.leonxie.com/referencegene.php), see Appendix B for more details. 
Relative expression values were then adjusted for PPC (to account for any inter-
plate variability), age, sex, current mood status, BMI and the presence of 
comorbid disorders (diabetes, cardiovascular problems). ΔCt were used in 
statistical calculations, and 2–ΔCt were used to generate bar charts (Livak & 
Schmittgen, 2001).  
To ascertain whether significant transcriptional differences existed 
between control, MDD and BPD subject groups in our discovery cohort, we 
performed analysis of variance (ANOVA) tests. Partial eta squared (ηp2) was 
calculated as an estimate of effect size, by dividing the sum of squares between 
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groups by the total sum of squares. Games-Howell post-hoc tests were 
subsequently performed to correct for multiple testing and to generate pair-wise 
comparisons between subject groups (Games & Howell, 1976). Based on results 
from the discovery cohort, we then performed one-tailed independent sample t-
tests to attempt to replicate findings in our validation cohort. 
We have previously shown that escitalopram does not affect the 
transcription of inflammatory cytokines in our MDD patient sample, with the 
exception of ATP-binding cassette sub-family F member 1, which has been 
excluded as a potential biomarker (see Powell et al., 2013, or Chapter 6). 
However, medications used in our BPD patient sample may affect transcription, 
and as such we performed post-hoc analyses to assess whether these medications 
may represent confounding factors. Consequently, for each gene’s expression 
that significantly differentiated our BPD subjects from either controls or MDD 
patients, we ran univariate linear regressions for our BPD sample only. The 
expression of the significant gene was selected as the dependent variable and 
regularly used medications included as covariates. For any medications which 
significantly predicted the expression of a gene, we excluded that transcript as a 
likely biomarker.  
For any transcripts that significantly differentiated MDD patients from 
control subjects or BPD patients, in both the discovery and validation cohorts, 
we performed an additional test to determine the stability of these transcripts as 
state biomarkers for MDD. We achieved this by utilising transcript data 
generated from blood collected at a different time point (start of GENDEP), 
under different conditions (patients were drug free, all patients were in a 
depressed episode). As before, we attempted to validate biomarkers by 
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3.4.1 Validation of internal controls 
All qPCR plates passed quality control checks outlined. 70 out of 87 target genes 
were sufficiently detectable according to our criteria. RefFinder analyses revealed 
that B2M, RPL13A and ACTB were the three most stable housekeeping genes 
across all samples and subsequently were selected for normalization purposes, 
see Figure 3.2.  
 
3.4.2 Transcriptional differences between subject groups 
 
3.4.2.1 Discovery Cohort 
ANOVA revealed 11 genes which showed nominally significant transcriptional 
differences (p ≤ 0.05) between our three subject groups. The most significant 
differences between subject groups were found in Chemokine (C-C motif) ligand 
24 [CCL24: F (2, 85) = 6.438, p = 0.002, ηp2 = 0.134] and interleukin-8 [IL8: F (2, 
87) =  6.872, p = 0.002, ηp2 = 0.136], see Appendix C for full ANOVA results. 
Games-Howell post hoc analyses were subsequently performed on all genes 
present on the array, see Appendix D for full results. These tests correct for the 
effects of multiple testing, and generate pairwise comparisons. Table 3.3 lists the 
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genes which produced significant p-values from the ANOVA analyses (p≤0.05) 
and details corrected pair-wise results generated from Games-Howell post hoc 
analyses. None of the medications used by our BPD patients significantly 
















Figure 3.2: A bar chart showing the results of RefFinder analyses performed on a 
panel of five housekeeping genes. The gene names of the housekeeping genes 
are indicated on the x-axis, along with their expression stability score shown on 

























3.4.2.2 Validation Cohort 
One-tailed independent t-tests were used in our validation cohort to test whether 
we could replicate potential biomarkers identified from our discovery cohort, see 
Table 3.4. Higher transcription of CCL24, the most significant difference 
revealed between subjects in our discovery cohort, again significantly 
differentiated MDD patients from controls (t = 2.394, d.f. = 23, p = 0.0125) and 
BPD patients (t = 2.674, d.f. = 23, p = 0.007) in the validation cohort, see Figure 
3.3. Lowered transcription of CCR6 also continued to differentiate MDD 
patients from controls in our validation cohort (t = -2.315, d.f. = 23, p = 0.015), 
see Figure 3.4. 
We additionally used one-tailed independent samples t-tests to observe 
whether CCL24 and CCR6 transcription continued to differentiate MDD 
patients from our other subject groups when blood was collected from a different 
time point. Again, we found that higher transcription of CCL24 significantly 
differentiated MDD patients from controls in our discovery cohort (t = 7.237, d.f. 
= 57, p ≤ 0.000001) and replication cohort (t = 6.603, d.f. = 23, p ≤ 0.000001) 
when MDD blood was collected from different time point. Similarly, we found 
that higher transcription of CCL24 significantly differentiated MDD patients 
from BPD patients in both our discovery cohort (t = 7.247, d.f. = 57, p ≤ 
0.000001) and replication cohort (t = 4.511, d.f. = 11.64, p ≤ 0.001). 
Additionally, lower transcription of CCR6 continued to differentiate MDD 
patients from controls in both our discovery cohort (t = -1.841, d.f. = 58, p = 


























Figure 3.3: Bar charts showing the adjusted mean relative expression of CCL24 
(y-axis) in our control subjects, MDD patients and BPD patients (x-axis) using 
data collected from our (A) Discovery cohort, and (B) Validation cohort. Error 
bars represent standard error. Significant differences between subject groups are 





Figure 3.4: Bar charts showing the adjusted mean relative expression of CCR6 (y-
axis) in our control subjects, MDD patients and BPD patients (x-axis) using data 
collected from our (A) Discovery cohort, and (B) Validation cohort. Error bars 
represent standard error. Significant differences between subject groups are 




Mood disorders are heterogeneous disorders that are diagnosed through patients 
displaying a number of clinical characteristics. The absence of a specific and 
objective diagnostic test has led to relatively high rates of misdiagnosis for mood 
disorders, particularly between MDD and BPD patients (Lewis et al., 2003). 
Recent reports have revealed differences in cytokine gene expression between 
MDD patients and controls, and BPD patients and controls (Padmos et al., 
2008; Cattaneo et al., 2012). This follows a growing body of evidence linking 
inflammation with mood disorder pathophysiology and response to mood 
disorder pharmacotherapies (Raison et al., 2006; Dantzer et al. 2008; Uher et al., 
2010; Powell et al., 2012b; Powell et al., 2013a, Powell et al., 2013b).  
Here, we attempted to identify transcriptional differences in the 
inflammatory cytokine pathway between MDD, BPD and control subjects in a 
‘discovery cohort’, and to assess whether these differences might act as 
biomarkers to differentiate between subject groups in a ‘validation cohort’. 
Results from our discovery cohort revealed 11 transcripts which differentiated 
between our subject groups (see Table 3.3). The majority of these transcripts 
coded for chemokines and chemokine receptors. However, two notable 
exceptions include interleukin-8 (IL8) and the glucocorticoid receptor (NRC31). 
Previous reports have found lowered levels of IL-8 protein in the blood of MDD 
patients relative to controls, and within the cerebrospinal fluid of suicide 
attempters compared to controls (Simon et al., 2008; Lehto et al., 2010; Isung et 
al., 2012). In the current study we found that lower transcription of IL8 
distinguished both types of mood disorder patient (MDD and BPD) from 
control subjects (see Table 3.3). This may suggest that a common molecular 
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pathway impacting upon the transcription of IL8 could be involved in mood 
disorder pathophysiology. We also found that MDD patients exhibited 
decreased transcription of NRC31 relative to control subjects (see Table 3.3). 
Lowered expression of NRC31 has previously been reported both at the protein 
and transcriptional level amongst MDD patients, and altered expression and 
functionality of NRC31 has a recognised role in the pathophysiology of MDD 
(Pariante & Miller, 2001). However, neither IL8 nor NRC31 transcripts 
significantly differentiated between subject groups in our validation cohort, which 
suggests that although they may be involved in mood disorder pathophysiology, 
they may not be reliable or specific enough to be utilised as biomarkers.  
In contrast, higher transcription of CCL24 consistently differentiated 
MDD patients from control and BPD subjects, and lower transcription of CCR6 
consistently differentiated MDD patients from controls, in both our discovery 
and replication cohorts (see Figure 3.3 and Figure 3.4). The transcription of 
these genes continued to differentiate MDD patients from other subject groups 
even when MDD blood was utilised from a different time point (see Section 3.4 
Results), corroborating the notion that transcriptional differences in these genes 
likely relate to long-lasting state differences associated with MDD, as opposed to 
trait differences.   
Both CCL24 and CCR6 code for genes in the chemokine cytokine 
family. The chemokines are small ‘chemotactic’ cytokines that facilitate the 
migration of immune cells (e.g. to a site of infection; Lehto et al., 2010). CCL24 
codes for a chemokine which is chemotactic for resting T lymphocytes, 
eosinophils, and to a lesser extent neutrophils (Patel et al., 1997; White et al., 
1997). In contrast, CCR6 codes for a G-protein coupled receptor present on 
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immature dendritic cells, B-cells and memory t-cells, and binds macrophage 
inflammatory protein 3 alpha (Ai et al., 2004). Chemokines have previously been 
implicated as potentially important cytokines in the pathophysiology of MDD 
and higher levels of chemokine proteins have previously been revealed amongst 
MDD patients relative to controls (Miller et al., 2008; Lehto et al., 2010). 
However, this is the first study to identify CCL24 and CCR6 transcripts as 
potential diagnostic biomarkers. 
In addition to gene transcription offering a more objective method of 
clinical diagnosis, the fact that it is also a continuous measure gives it certain 
advantages over currently utilised categorical measures. For instance, continuous 
or dimensional diagnostic measures are believed to be more stable over time, 
offer a better measure of symptom severity, and be better predictors of 
comorbidity and chronicity (Clark et al., 1995; Watson, 2005). Consequently, 
transcriptional measures, such as those reported here, could be combined with 
phenomenological or symptom dimension measures in future diagnostic 
manuals to more sensitively capture clinically useful information for MDD and 
BPD diagnosis.  
Although results reported here are promising, there are four main 
limitations to this study. Firstly, this study utilises relatively small sample sizes, 
and although we use both a discovery and replication cohort, patients were 
obtained as subsamples from the same studies, so it only offers a pseudo-
independent replication. Therefore replication studies are required in a larger 
independent sample. Secondly, although we considered the effects of different 
medications on gene expression profiles, all of our patients were medicated. 
Based on our previous work on the MDD patient sample used here, we can, with 
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some confidence, rule out the confounding effects of escitalopram treatment (see 
Powell et al., 2013). This was further supported by analyses on our MDD 
patients after they were medication-free for two weeks (see Section 3.4 Results). 
However, our BPD patient cohort were all treated with a variety of medications, 
and although we could rule out the confounding effects of each medication 
separately, we could not assess whether common actions of different medications 
may have confounding effects on gene transcription in our sample. Therefore 
future studies in drug-free patients are required in order to validate the transcript 
biomarkers identified in this study. Thirdly, although we accounted for 
differences in BMI, cardiovascular problems and diabetes between our subject 
groups, we did not have an extensive account of comorbidities. Comorbid 
ailments such as chronic pain, irritable bowel syndrome and arthritis are known 
to be more frequent amongst mood disorder patients and they likely affect 
cytokine expression (Leboyer et al., 2012), and thus a more extensive list of 
comorbid disorders should be accounted for in future studies. Finally, without 
cell count information we cannot determine the cell types that may be driving our 
observed transcript differences between subjects.  
Despite its limitations, the current study utilises well-characterized clinical 
samples, stringent quality control steps, normalisation protocols and statistical 
analyses. This study supports previous reports of differences in the expression of 
IL8 and NR3C1 amongst mood disorder patients. However, the lack of 
replication in our validation cohort suggests that differences in the transcription 
of these genes may not be reliable enough to be utilised as biomarkers. Instead, 
this study emphasized the potential importance of chemokines as biomarkers, 
and specifically it identifies the potential utility of CCL24 and CCR6 transcripts 
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as novel biomarkers differentiating MDD patients from control subjects and 
BPD patients. If replicated in other studies, these transcripts could be used in 
conjunction with symptom measures to more accurately diagnose MDD from the 
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Figure 4.0: A picture showing the complex interactions between immune cells, 
orchestrated through the release of different types of inflammatory cytokines. 
Adapted from 




This chapter consists of a manuscript published in European 
Neuropsychopharmacology in November 2012. For more information on the 
pressing need for biomarkers as predictors of antidepressant response, see 
Sections 1.4.2. For more information on previous work relating to cytokines as 
biomarkers for antidepressant response see Section 1.5.1.2. For more 
information on RNA see Section 2.3.3.1. For more information on RNA quality 
controls steps see Section 2.2.3.3. and 2.2.3.4. For more information on qPCR 
methodology, see Section 3.2.2.2.  
For consistency with the wider thesis, Section 1. Introduction in this 
manuscript is referred to as Section 4.1 elsewhere, Figure 1 within the 
manuscript will be referred to as Figure 4.1, Table 1 will be referred to as Table 
4.1 etc. geNorm and Normfinder analyses described in this manuscript are an 
earlier variation of the RefFinder analyses described in Section 3.3, used for 
reference gene selection. The Supplementary Information mentioned in the 



























































































































Investigating the utility of DNA 
methylation in interleukin-11 as a 








Figure 5.0: This image shows a DNA molecule that is methylated on both 




This chapter consists of a manuscript published in Translational Psychiatry in 
September 2013. This work follows results described in Chapter 4. For more 
information on previous work relating to epigenetics and MDD, see Section 
1.1.7. For consistency with the wider thesis, Introduction in this manuscript is 
referred to as Section 5.1 elsewhere, Figure 1 within the manuscript will be 
referred to as Figure 5.1, Table 1 will be referred to as Table 5.1 etc. 
The method for DNA methylation quantification employed in this 
chapter was developed by Elrich et al. 2005. Briefly, the method uses bisulfite 
treatment to produce DNA methylation-dependent sequence changes, 
converting non-methylated cytosine nucleotides to thymine. These 
cytosine/thymine variations appear as guanine/adenine changes on the reverse 
strand, which result in a mass difference of 16 Da per CpG site in the cleavage 
products that have CpG sites. The mass difference is then detected by the 
MassARRAY system contributing to differential signal pattern, which allows us to 


















































































Investigating the effects of 
escitalopram treatment on 
transcription within the 







Figure 6.0: A computer generated image of the chemical 





This chapter consists of a manuscript published in Journal of 
Psychopharmacology published in July 2013. For more information on 
escitalopram see Section 1.3.1.1. For more information on antidepressant-
induced transcriptional changes and treatment-emergent biomarkers for 
antidepressant response see Section 1.5.1.3. For consistency with the wider 
thesis, Introduction in this manuscript is referred to as Section 6.1 elsewhere, 
Figure 1 within the manuscript will be referred to as Figure 6.1, Table 1 will be 




















































































































Figure 7.1: ‘Teen Depression’, an illustration by Robert 
Carter. 
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7.1 Summary of findings from this thesis 
 
The main aims of this thesis were to identify novel gene-environment interactions 
contributing to MDD, to search for molecular biomarkers which might be used 
to aid clinical diagnosis and treatment selection for MDD, and to investigate the 
molecular effects of antidepressant treatment. Our first aim was addressed in 
Chapter 2, where we attempted to identify potentially novel gene-environment 
interactions, which might increase an individual’s risk to MDD. We achieved this 
by investigating transcriptomic changes in the hypothalamus in response to 
maternal separation, using two inbred strains of mice; one of which showed long-
lasting alterations in HPA-reactivity (C57BL/6J) and another which did not show 
changes in HPA-reactivity (DBA/2J). The aim was to model an early life stress, 
analogous to childhood neglect, in both mouse strains and investigate whether 
stress by strain interactions present at the level of the transcriptome in mouse 
could be used to prioritise the search for gene-environment interactions for 
MDD in humans. Our top stress x strain interaction in the mouse transcriptome 
was in Terc, which codes for the RNA component of the enzyme telomerase, 
used in the extension of telomeres. Telomeres have previously been found to be 
shorter amongst adults who have experienced early childhood neglect, and 
amongst mood disorder patients (Tyrka et al., 2010; Simon et al., 2006; 
Hartmann et al., 2010; Elvsashagen et al., 2011; Wikgren et al., 2012). Consequently, 
differential changes in Terc expression could offer a mechanism through which 
early stresses, such as neglect, evoke long-lasting alterations in telomere length. 
We further found an interaction between a SNP downstream of TERC 
(rs10936599) and severity of childhood emotional neglect which predicted MDD 
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case/control status in a human clinical cohort. As rs10936599 has previously 
been identified as the strongest genetic predictor of telomere length (Codd et al., 
2013), it further supports the notion that molecular differences in TERC 
interacting with childhood emotional neglect may be responsible for differential 
telomere length, and is subsequently associated with MDD case/control status. 
 Our second aim was addressed in Chapter 3, where we attempted to 
identify molecular biomarkers to aid clinical diagnosis of MDD. Specifically we 
aimed to investigate whether transcriptomic biomarkers within the inflammatory 
cytokine pathway could be used to differentiate between control subjects, BPD 
patients and MDD patients. This study revealed that specific differences in the 
transcription of the chemokines CCL24 and CCR6 could differentiate MDD 
patients from BPD patients and control subjects. This subsequently suggests that 
disorder-specific differences in the transcription of chemokines might be useful 
clinically in differentiating MDD patients from BPD patients, helping to prevent 
misdiagnosis and the prescription of inappropriate pharmacotherapies. 
 Our third aim was to identify molecular predictors of antidepressant 
response and this was addressed in Chapters 4 and 5. In Chapter 4 we found that 
the transcription of TNF and its targets in the inflammatory cytokine pathway 
predicted clinical response to the SSRI antidepressant escitalopram. We further 
identified a treatment-emergent expression quantitative trait locus in IL11; 
whereby a SNP in IL11 (rs1126757) identified as the best predictor of 
escitalopram response from a GWAS was associated with differential expression 
changes in response to the drug which corresponded with clinical response. In 
Chapter 5 we investigated whether DNA methylation in IL11, another baseline 
molecular factor known to affect gene expression, might also predict 
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antidepressant response or interact with rs1126757 to predict response. We 
found CpG-unit specific methylation differences within IL11 which: predicted 
general antidepressant response; differentially predicted response to two different 
antidepressants with differing mechanisms of action (escitalopram and 
nortriptyline); interacted with rs1126757 to predict antidepressant response. 
Consequently, Chapter 4 details one of the first studies to identify transcriptomic 
predictors of antidepressant response, and Chapter 5 details the first study to 
identify putative baseline epigenetic predictors of antidepressant response.  
 Our final aim was addressed in Chapter 6 where we investigated whether 
the SSRI escitalopram induces changes to the transcription of genes within the 
inflammatory cytokine pathway, and whether such changes related to clinical 
response. We found significant increases in the transcription of ABCF1 in 
response to escitalopram, with changes corresponding to clinical response. As 
ABCF1 is a translational regulator of the inflammatory cytokines, changes to its 
transcription may represent the mechanism through which antidepressants evoke 
changes to cytokine protein levels (e.g. Kenis & Maes, 2002). These results are 
the first to suggest that ABCF1 may act as a novel therapeutic target of 
escitalopram.  
 
7.2 Implications of Research Findings 
Findings from Chapter 2 suggest that the maternal separation protocol in animal 
models might be useful in identifying novel susceptibility loci for MDD. Our 
findings specifically have potentially important implications for the prevention of 
MDD in a particular subgroup of individuals. Our results suggest that genetic 
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polymorphisms within TERC, with the ability to affect telomerase activity and 
telomere length, interact with childhood emotional neglect to predispose to 
MDD in adulthood. If our findings were replicated, and it was found that 
changes in TERC expression relate to a causative pathway of MDD, prevention 
strategies could be created. For instance, drugs, diet or exercise regimes which 
increase telomerase activity could be developed and prescribed to those with the 
risk-allele who have experienced childhood neglect in order to reduce their 
chances of developing MDD.  
 Results from Chapter 3 have two main implications. First, they suggest 
that transcriptional differences in the chemokines CCL24 and CCR6 could aid 
clinical diagnosis of MDD, differentiating MDD suffers from BPD individuals 
and healthy control subjects. If replicated, this could have important clinical 
implications, helping to improve diagnosis from the outset and prevent the 
prescription of inappropriate medication. Secondly, it may suggest that these two 
chemokines are specifically related to the pathophysiology of MDD and 
subsequently may represent important novel drug targets. 
 Results reported in Chapters 4 and 5, if replicated, could be used to 
improve treatment selection for MDD patients. We find evidence that molecular 
biomarkers in blood may be utilised as clinical predictors of antidepressant 
response. As only one-third of patients respond to the first antidepressant 
prescribed (Gibson et al., 2010), our findings have potentially very important 
implications in improving treatment response from the outset. The results in 
Chapter 5 are the first to find baseline epigenetic predictors of antidepressant 
response, providing the first preliminary evidence that pharmaco-epigenetics may 
be important in MDD treatment. In addition to finding epigenetic predictors of 
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general antidepressant response, we also identified differences in CpG-unit 
methylation which differentially predicted response to two antidepressants of 
different mechanisms of action. Consequently, if replicated, this could be utilised 
clinically to establish which type of antidepressant is best suited to each individual 
as quickly as possible, and it could reduce the costs associated with ineffective 
treatment.  
 Based on findings reported in Chapters 4 and 5, drugs targeting either 
TNF or IL11 may prove useful as adjuvant therapies for MDD treatment. In 
fact, a recent study suggests that adjuvant treatment with the TNF antagonist 
infliximab may help to improve antidepressant response  (Raison et al., 2013). 
Results from Chapter 6 also suggest that ABCF1 may act as a therapeutic target 
of escitalopram and therefore drugs targeting ABCF1 may also be useful in 
treating MDD and improving response rates. 
 
7.3 Future Directions 
Based on the results detailed in this thesis, we can suggest numerous future 
research directions. Future studies should investigate the relationship between 
early life stress, TERC expression, telomerase activity and telomere length, with 
relation to MDD. This could best be achieved using a longitudinal study design 
in humans. Furthermore, a parallel mouse study could be used to establish 
whether differences in telomere length in a human peripheral tissue (e.g. 
lymphocytes) in response to early stress correspond with changes occurring in the 
brain. 
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 In Chapter 3, we found transcriptional differences in CCL24 and CCR6 
differentiated MDD patients from other subject groups. These findings require 
replication in a larger, drug-free patient cohort, and further analysis is required to 
determine how accurately these measures can be used to diagnose patients 
prospectively. As discussed in Section 1.5, biomarkers at different biological 
levels can potentially provide distinct, clinically useful information. Therefore, 
future studies should also establish whether genetic, epigenetic, or proteomic 
differences in CCL24 or CCR6 might also contain biomarker properties and 
whether differences at these molecular levels better differentiate MDD patients 
from other subject groups. Similarly, both TNF protein levels (e.g. Eller et al., 
2008) and TNF transcription (reported in Chapter 4) have been found to predict 
response to escitalopram, thus future studies should evaluate which molecular 
measure more reliably captures response, and whether TNF specifically predicts 
response to the SSRI class of antidepressant only.  
 Based on results from Chapter 5, future research into antidepressant 
treatment response should consider the use of pharmaco-epigenetic biomarkers. 
As this study was the first of its kind, replication is essential. If IL11 is confirmed 
as an epigenetic predictor of antidepressant response, it warrants the use of whole 
genome methods to assess whether other methylomic regions across the genome 
may also offer clinically useful biomarker information. Furthermore, as our 
results also revealed interactions between genomic factors and DNA methylation 
predicting antidepressant response, future statistical methods should be 
developed to incorporate genomic and methylomic data on a genome-wide scale.  
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7.4 Concluding Remarks 
MDD is a complex heterogeneous disorder with both environmental and genetic 
risk factors. Through dissecting distinct aetiological pathways it may be possible 
to identify gene-environment interactions that contribute to the development of 
MDD. Furthermore, in the case of childhood neglect, it may be possible to 
model this in animals, and use molecular changes in mouse brain to prioritize 
the investigation of gene-environment interactions for MDD in humans. One 
interaction identified here is between genetic differences in TERC and childhood 
neglect which may predict MDD status in adulthood. Inflammatory cytokines 
show important interactions with the brain and may harbour the potential to be 
important biomarkers for MDD. Transcriptional differences in the chemokines 
CCL24 and CCR6 may act as useful biomarkers for MDD. Transcriptional 
differences in the TNF family and DNA methylation in IL11 may act as useful 
predictors of antidepressant response. Furthermore, ABCF1, a gene coding for a 
translational regulator of the inflammatory cytokine pathway shows 
transcriptional changes in response to antidepressant treatment which 
correspond to antidepressant response, and so may represent an important novel 
drug target. If results reported here are replicated in larger studies in the future, 
this area of research may ultimately contribute towards the improved 
identification of individuals at risk for MDD, improved diagnosis of MDD, and 
may aid the development of targeted therapies for individual patients on the basis 
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of mood-stabil izers on housekeeping gene expression stabil i ty. 
 
Mood-stabil izers differential ly affect housekeeping gene expression 
in human cells 
Timothy R. Powell1*, Georgia Powell-Smith1, Kate Haddley2, Peter McGuffin1, 
John Quinn2, Leonard C. Schalkwyk1, Anne E. Farmer1, Ursula M. D’Souza1 
 
 
1MRC Social Genetic and Developmental Psychiatry (SGDP) Centre, Institute of 
Psychiatry, King’s College London, PO 80, Denmark Hill, London, SE5 8AF, 
UK  
2 Department of Molecular and Clinical Pharmacology, Institute of Translational 
Medicine, University of Liverpool, Ashton Street, Liverpool, L69 3GE, UK 
 
* Correspondence to Timothy R Powell, MRC Social Genetic and 
Developmental Psychiatry (SGDP) Centre, Institute of Psychiatry, King’s College 
London, PO 80, Denmark Hill, London, SE5 8AF, UK. Telephone No: + 207-
848-0384. Fax No: +207-848-0866 Email: timothy.powell@kcl.ac.uk 
 







Recent studies have revealed that antidepressants affect the expression of 
constitutively expressed “housekeeping genes” commonly used as normalizing 
reference genes in quantitative PCR (qPCR) experiments. There has yet to be an 
investigation however on the effects of mood-stabilizers on housekeeping gene 
stability. The current study utilized lymphoblastoid cell lines (LCLs) derived 
from patients with mood disorders to investigate the effects of a range of doses of 
lithium (0, 1, 2 and 5 mM) and sodium valproate (0, 0.06, 0.03 and 0.6 mM) on 
the stability of twelve housekeeping genes. RNA was extracted from LCLs and 
qPCR was used to generate cycle threshold (Ct) values which were input into 
RefFinder analyses. The study revealed drug-specific effects on housekeeping 
gene stability. The most stable housekeeping genes in LCLs treated: acutely with 
sodium valproate were ACTB and RPL13A; acutely with lithium were GAPDH 
and ATP5B; chronically with lithium were ATP5B and CYC1. The stability of 
GAPDH and B2M were particularly affected by duration of lithium treatment. 
The study adds to a growing literature that the selection of appropriate 
housekeeping genes is important for the accurate normalization of target gene 










Mood-stabilizers such as lithium and sodium valproate are commonly prescribed 
pharmacotherapies used in the treatment of bipolar disorder. Despite being 
clinically prescribed, the mechanisms of action of each of these drugs are still 
relatively unknown (Shaldubina et al., 2001). It is largely accepted however that 
gene expression changes associated with these drug treatments likely play a role 
in their therapeutic effects (Sugawara et al., 2010). Numerous studies using 
patient tissue samples such as brain and blood have attempted to unearth the 
molecular pharmacology of these mood-stabilizing drugs and how they confer 
their therapeutic effects (MacQuillin et al., 2007; Chetcuti et al., 2006; Tsuang et 
al., 2005). The quantitative polymerase chain reaction (qPCR) is the standard 
method of investigating candidate gene expression changes and is used to validate 
large-scale microarray expression hits (VanGuilder et al., 2008).  
qPCR is a reaction in which a particular gene or region of DNA is 
amplified and detected in real-time. The relative quantification method of 
normalization is often employed for qPCR data and requires the subtraction of 
relatively stable reference genes’ expression from the potentially more dynamic 
expression of the target gene (Livak & Schmittgen, 2001). As the reference genes 
used for normalization are subject to the same conditions as the target gene itself, 
it helps to control for variables such as RNA integrity and reverse transcription 
efficiency, as well as controlling for differences in the amount of starting material. 
 Most studies have used so-called ‘housekeeping’ genes as the reference 
genes for normalization, as the products of these genes are essential for basal cell 
metabolism and so are assumed to be expressed at a constant and detectable 
level in all nucleated cell types during all developmental stages (Thellin et al., 
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1999). Many of the commonly used housekeeping genes such as beta-actin 
(ACTB), glyceraldehyde 3-phosphate dehydrogenase (GAPDH), 18S rRNA 
(18S) and beta-2-microglobulin (B2M) were first used in traditional qualitative or 
semi-quantitative methods because of their high expression levels in all cells 
(Hendriks-Balk et al., 2007). 
Recent research however suggests that housekeeping genes are not as 
stable as was originally thought, with evidence demonstrating different levels of 
stability in different cell types (Vandesompele et al., 2002) and conditions (Hruz 
er al., 2011). Previous studies have reported that antidepressants cause changes 
to the expression of housekeeping genes (Sugden et al, 2010; Powell et al., 2012). 
For instance, Sugden et al (2010) investigated the effects of antidepressants on 
housekeeping gene expression in a mouse fibroblast cell line. It was revealed that 
antidepressants affect housekeeping gene expression stability with some genes 
(ATP synthase and cytochrome c1) showing greater levels of stability than others 
[Eukaryotic translation initiation factor 4A2 (Eif4a2)].  
Subsequently, the selection of appropriate housekeeping genes is 
important for the accurate normalization of gene expression experiments 
investigating the molecular effects of pharmacotherapies for unipolar depression. 
However, there is no evidence as to whether mood-stabilizers used to treat 
bipolar disorder also affect the expression of housekeeping genes. In this study 
we aimed to investigate the in vitro effects of the mood-stabilizers lithium and 
sodium valproate on the expression of a panel of candidate housekeeping genes 
using mood disorder patient-derived lymphoblastoid cell lines (LCLs) treated 
with these drugs. We aimed to establish: the most appropriate reference genes 
for LCLs treated with each drug, the most inappropriate reference genes for 
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LCLs treated with each drug, and the effects of drug treatment duration on 
housekeeping gene stability.  
 
Materials and Methods 
Participants  
Samples in this study were collected as part of the Depression Case Control 
(DeCC) Study. The clinical methodology used in the DeCC collection was 
described in detail previously (see Gaysina et al., 2007).  Briefly, subjects were 
identified from psychiatric clinics, hospitals, and general medical practices, and 
from volunteers responding to media advertisements. Only subjects of White 
European parentage were included. Subjects were over the age of 18 and had 
experienced two or more episodes of unipolar depression of at least moderate 
severity separated by at least two months of remission as defined by the 
Diagnostic and Statistical Manual 4th edition operational criteria (DSM-IV), or 
the International Classification of Diseases 10th edition operational criteria 
(ICD10). Participants were excluded if they had schizophrenia or bipolar 
disorder or their depression was caused by a physical illness, medication, alcohol 
or substance abuse, if they were intravenous drug users or were related to 
someone already recruited for the study. The study was approved by the Joint 
South London and Maudsley NHS Trust Institute of Psychiatry Research Ethics 
Committee and informed written consent was obtained from all the participants 
at the time of sample collection. 10 ml of whole blood from individuals was sent 
to the Human Genetic Cell Bank at the European Collection of Cell Cultures 
(ECACC), during which immortalised epstein-barr virus (EBV)-transformed 
lymphoblast cell lines (LCLs) were generated. The current study utilized LCLs 
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from five females diagnosed with unipolar depression, with a mean age of 53.6 ± 
11.7 years, and who had not previously taken any mood-stabilizing medications. 
 
Cell culture  
The LCL samples were supplied by ECACC as frozen ampoules containing 1 
mL of cells at a density of approximately 2 x 107 cells/mL, in cell culture freezing 
medium [10 % dimethyl sulphoxide (DMSO)]. Five cell lines were selected and 
grown in suspension in RPMI-1640 medium (Sigma-Aldrich, Poole, UK) 
supplemented with 10 % foetal bovine serum, 2 mM L-glutamine, 100 units/mL 
penicillin, 0.1 mg/mL streptomycin and 0.05 mg/mL neomycin at 37°C in a 
humidified atmosphere containing 5% CO2 (see S1).  
 
Drug Treatment of LCLs 
The lithium chloride drug (Sigma-Aldrich) dilution was prepared by diluting the 
supplied 8 M LiCl solution in RNAase-free water to produce a sterile 1 M LiCl 
stock solution, and then further diluting the stock solution to 1, 2 and 5 mM for 
the treatment procedure. Sodium valproate (Sigma-Aldrich) was obtained in 
powder form and diluted in RNase-free water to a concentration of 3 mM. This 
stock solution was then diluted accordingly to concentrations of 0.06, 0.3 and 0.6 
mM for the treatment procedure. A vehicle control dilution was also prepared 
using RNase-free water in serum-free supplemented growth medium. 
Each of the five cell lines underwent an acute drug treatment as part of a 
four-stage culture protocol: (i) 72-hour growth phase, (ii) 24-hour serum-starve 
phase, (iii) 24-hour drug administration, and (iv) 24-hour recovery phase (for 
details see S2). After the final 24-hour recovery phase, cell pellets were obtained 
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following centrifugation and were immediately stored at -80 ºC for RNA 
extraction. 
            Each of the five cell lines were also treated with a chronic 7-day dose of 
LiCl. This involved the same doses as with the acutely treated cells but instead 
utilized a two stage culture protocol: (i) 72-hour growth phase and a (ii) 7-day 
lithium administration phase (see S3 for details). 
 
RNA extraction and cDNA synthesis 
RNA extraction was performed using TRI reagent (Sigma-Aldrich). The purity 
and quantity of RNA was subsequently measured using the Nanodrop, ND1000, 
which showed all samples had 260/280 ratios of between 1.8 and 2.1. The RNA 
integrity numbers (RINs) of samples were assessed using the Agilent 2100 
Bioanalyzer and all samples showed RINs > 9. The reverse transcription reaction 
was prepared using 1 µg of total RNA and the QuantiTect Reverse Transcription 
Kit (Qiagen, Crawley, UK). Complementary DNA (cDNA) synthesis was carried 
out in two steps: a genomic DNA (gDNA) wipe-out step, followed by reverse 
transcription step, as according to the manufacturer’s protocol. Briefly, following 
gDNA removal, the samples were incubated for 15 minutes at 42°C with 1 uL 
Quantiscript Reverse Transcriptase, 5 X Quantiscript RT buffer, and 1 uL RT 
primer mix (oligo-dT and random primers). The reverse transcriptase enzyme 
was subsequently inactivated at 95°C for 3 minutes. The cDNA samples 





The qPCR experiments were performed in 384-well plates using reagents from 
Primer Design (Southampton, UK). Reagents included Precision-R MasterMix 
and the human geNorm Kit (PrimerDesign) which included 12 pre-designed 
PerfectProbeTM fluorescent (FAM-labelled) primer/probe sets for 12 human 
housekeeping genes. No Ct values for the housekeeping gene Eif4a2 were 
detected in our samples. This was due to a technical problem with the 
primer/probe set that had been supplied for this gene. Therefore the gene Eif4a2 
was excluded from the assays and from the final analyses. Details of the 
remaining 11 housekeeping genes are shown in Table 1 (see S4 for more 
detailed information on primers). The qPCR was set up according to the 
manufacturer’s instructions, whereby each well on our 384-well plate contained a 
20 µL qPCR reaction mixture consisting of: 5 µL cDNA, 4 µL RNase-free water, 
1 µL of primer/probe mix and 10 µL of Precision-R MasterMix. qPCR assays 
were performed in duplicate to generate two technical replicates, and a negative 
control sample was also included for each reference gene.  
The qPCR reactions were performed using the ABI Prism 7900HT 
Sequence Detection System (Applied Biosystems, California, USA). Thermal 
cycling conditions consisted of an enzyme activation stage (95°C for 10 minutes), 
followed by 50 cycles of a denaturation stage (95°C for 15 seconds) and 
hybridization and data collection stage (50°C for 30 seconds), and a final 
extension stage (72°C for 15 seconds). The software program SDS 2.1 (Applied 







Table 1: A list of the 11 housekeeping genes included in the human geNorm kit, 
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Topoisomerase (DNA) I (TOP1) 
 
 
Enzyme that controls and alters 












Subunit of mitochondrial ATP 
synthase, produces ATP from 
ADP using a protein gradient 
across the membrane 
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Statistical Analysis 
Average Ct values from our technical replicates were input into The RefFinder 
statistical analysis web-based tool (available from 
http://www.leonxie.com/referencegene.php). This tool was used for evaluating 
the stability of putative reference genes using an integrative weighted analysis 
which incorporates results from four already established analyses used for the 
selection of reference genes. These four already established statistical analyses for 
the selection of reference genes include: geNorm [as described in Vandesompele 
et al. (2002)], Normfinder [as described in Andersen et al. (2004)], Bestkeeper 
[as described in Pfaffl et al. (2004)] and the comparative ΔCt method [as 
described in Silver et al. (2006)]. Based on the rankings from each method, 
RefFinder assigns an appropriate weight to an individual gene and calculates the 
geometric mean of their weights for the overall final ranking.  
geNorm analysis was also considered separately as it can additionally be 
used to calculate the optimal number of reference genes required for 
normalization purposes. It achieves this by calculating standard deviations of log-
transformed expression ratios for all housekeeping genes and then carrying out a 
pairwise comparison of the standard deviation of a particular gene with each of 
the remaining other housekeeping genes. One by one, the least stable reference 
genes are excluded based on high M values (which represent expression stability 
scores), leaving at least two remaining genes that correspond to the most stably 
expressed genes. According to Vandesompele et al. (2002), a combination of two 
or more reference genes producing a V (variation measure) of V < 0.15 is 




(i) Number of reference genes required for accurate normalization 
The geNorm approach was used to establish the number of reference genes for 
accurate normalization.  The analysis revealed that two reference genes were 
optimal, as three reference genes would not increase accuracy above that 
obtained using two reference genes. The variation between the mean of the two 
most stable genes compared with that of the three most stable was V = 0.05 for 
acute lithium treated cells, V = 0.04 for chronic lithium treated cells, and V = 
0.04 for acute sodium valproate treated cells; all of which are well below the 
threshold of V<0.15 proposed by Vandesompele, et al. (2002). The pairwise 
variation was relatively stable across all the comparisons, none of which exceeded 
the threshold value of 0.15 (see S5-S7). Nevertheless, the selection of the most 
stable housekeeping genes will likely increase the chances of detecting target gene 
expression differences of smaller magnitudes. 
 
(ii) Acute treatment (24 hours) of LCLs with sodium valproate  
The Ct values of 11 housekeeping genes in LCLs treated with the different 
concentrations of sodium valproate are shown in Figure 1A. The lowest 
generated mean Ct value, and therefore the most highly expressed gene was 18S 
(16.87 ± 0.19 S.D). The highest mean Ct value and therefore the lowest 
expressing gene was SDHA (30.11 ± 0.67 S.D).  RefFinder analyses revealed that 
ACTB and RPL13A were the two most stable reference genes producing stability 
scores of 1.32 and 1.68 respectively. The two most unstable reference genes were 
SDHA and CYC1 producing stability scores of 9.24 and 10.24 respectively, see 
Figure 1B. Results from each of the individual analyses contributing to RefFinder 
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results (geNorm, Normfinder, Bestkeeper and the comparative ΔCt method) can 






Figure 1A: qPCR cycle threshold values generated for 11 reference genes in 
LCLs treated with a range of sodium valproate concentrations (0, 0.06, 0.3 or 
0.06 mM) for 24 hours. Expression levels are shown as median (lines), 25th 
percentile to the 75th percentile (boxes), and ranges (whiskers). The mean Ct 








Figure 1B: Bar chart showing RefFinder expression stability values (y-axis) for 11 
reference genes (x-axis) in LCLs treated with a range of sodium valproate 
concentrations (0, 0.06, 0.3 or 0.6 mM) for 24 hours. 
 
(ii) Acute treatment (24 hours) of LCLs with lithium  
The cycle threshold (Ct) values of 11 housekeeping genes in LCLs treated with 
different concentrations of lithium for 24 hours are shown in Figure 2A. The 
lowest mean Ct value, and therefore most highly expressed gene was 18S (18.79 ± 
1.74 S.D.), whilst the highest mean Ct value, and lowest expressed gene was 
succinate dehydrogenase complex, subunit A, flavoprotein (SDHA) (27.56 ± 
1.45 S.D.). RefFinder analyses revealed that GAPDH and ATP5B were the two 
most stable reference genes producing stability scores of 2 and 2.63 respectively. 
The two most unstable reference genes were SDHA and 18S producing stability 
scores of 9.49 and 11 respectively, see Figure 2B. Results from each of the 
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individual analyses contributing to RefFinder results (geNorm, Normfinder, 






Figure 2A: qPCR cycle threshold values in 11 reference genes in LCLs treated 
with a range of lithium chloride concentrations (0, 1, 2 or 5 mM) for 24 hours. 
Expression levels are shown as median (lines), 25th percentile to the 75th 
percentile (boxes), and ranges (whiskers). The mean Ct values (white diamonds) 








Figure 2B: Bar chart showing RefFinder expression stability values (y-axis) for 11 
reference genes (x-axis) in LCLs treated with a range of lithium chloride 
concentrations (0, 1, 2 or 5 mM) for 24 hours.  
 
 (iii) Chronic treatment (7 days) of LCLs with lithium  
The cycle threshold (Ct) values of 11 housekeeping genes in LCLs treated with 
different concentrations of lithium for 7 days are shown in Figure 3A. The lowest 
mean Ct value, and therefore most highly expressed gene was 18S (18.26 ± 0.60 
S.D.), whilst the highest mean Ct value, and lowest expressed gene was SDHA 
(29.28 ± 0.53 S.D.). RefFinder analyses revealed that ATP5B and CYC1 were 
the two most stable reference genes producing stability scores of 1.78 and 2.63 
respectively. The two most unstable reference genes were SDHA and ACTB 
producing stability scores of 10 and 11 respectively, see Figure 3B. Results from 
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each of the individual analyses contributing to RefFinder results (geNorm, 
Normfinder, Bestkeeper and the comparative ΔCt method) can be found in the 
S10. A comparison of the stability values of the housekeeping genes in LCLs 






Figure 3A: qPCR cycle threshold values in 11 reference genes in LCLs treated 
with a range of lithium chloride concentrations (0, 1, 2 or 5 mM) for 7 days. 
Expression levels are shown as median (lines), 25th percentile to the 75th 
percentile (boxes), and ranges (whiskers). The mean Ct values (white diamonds) 







Figure 3B: Bar chart showing RefFinder expression stability values (y-axis) for 11 
reference genes (x-axis) in LCLs treated with a range of lithium chloride 
concentrations (0, 1, 2 or 5 mM) for 7 days.  
 
Discussion 
Recent studies investigating the effects of antidepressants in vitro and ex vivo 
revealed that housekeeping gene expression, which was once believed to be 
‘stable’ across conditions, in fact shows expression variability (Sugden et al., 2010; 
Powell et al., 2012). This in turn has consequences for studies investigating the 
gene expression effects of mood disorder pharmacotherapies using qPCR 









Figure 4: Comparison of the 11 reference gene expression profiles for LCLs 
treated with a range of lithium chloride concentrations (0, 1, 2 or 5 mM) for 24 
hours (grey line) or for 7 days (black line). Gene names are shown on the x-axis 
and RefFinder stability values are marked on the y-axis.  
 
 
The current study aimed to investigate the effects of the mood-stabilizers lithium 
and sodium valproate, which are used to treat bipolar disorder, on housekeeping 
gene expression. This study investigated the effects of acute drug treatments 
(sodium valproate, lithium) and a chronic drug treatment (lithium) at a variety of 
doses on the expression of a panel of eleven housekeeping genes. The drug dose 
ranges chosen incorporates doses that are believed to be therapeutic. This is 
based on serum concentrations of lithium found in bipolar disorder patients 
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(approximately 1 mM) (Taylor et al, 2007), and on the dose required for sodium 
valproate to demonstrate neuroprotective effects (approximately 0.1 mM) 
(Biermann et al., 2011). The current study used an in vitro experimental design 
carried out using LCLs derived from mood disorder patients. LCLs have 
previously been shown to have gene expression profiles which correlate highly 
with levels of gene expression in non-transformed lymphocytes and whole blood 
collected from psychiatric patients (Rollins et al., 2010). Consequently, these cell 
lines were specifically selected from mood disorder patients with the aim of 
creating the best proxy model for investigating the gene expression effects of 
mood-stabilizers that may occur in vivo in mood disorder patients. 
 The study revealed that all housekeeping genes were expressed at 
acceptably detectable levels under drug treatment conditions (i.e. Ct < 37) in 
LCLs producing a broad range of Ct values (see Figures 1A, 2A and 3A). Across 
all drug groups, 18S was the most highly expressed housekeeping gene, whereas 
SDHA was the lowest expressing gene. Both mood-stabilizers were found to 
affect the stability of housekeeping gene expression and they did so differentially 
in a drug-specific manner. geNorm analyses revealed that two housekeeping 
genes were sufficient for optimal normalization of target genes in all drug 
treatment groups.  
In the LCLs treated acutely with sodium valproate, the two most stable 
housekeeping genes according to the RefFinder analyses were ACTB and 
RPL13A (see Figure 1B). ACTB, a gene encoding a cytoskeletal structural 
protein, has previously been used as a normalizing reference gene in mice treated 
with sodium valproate (Wu et al., 2010) and has been shown to be one of the 
most stable housekeeping genes in studies investigating the effects of valproate on 
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forskolin-stimulated human adrenal carcinoma (H295R) cells (Krogh et al., 
2010). RPL13A, a component of the 60S ribosomal subunit, has been shown to 
be one of the most stable housekeeping genes in a rat model of cerebral ischemia 
(Tian et al., 2007), but has not been previously used for normalization purposes 
in cells treated with sodium valproate. The housekeeping genes SDHA and 
CYC1 showed the highest expression variability according to RefFinder analyses, 
and thus would be considered unsuitable as reference genes in LCLs exposed 
acutely to sodium valproate (see Figure 1B).  
In the LCLs acutely treated with lithium, the two most stable 
housekeeping genes according to RefFinder were GAPDH and ATP5B (see 
Figure 2B). GAPDH, a gene encoding a glycolytic pathway enzyme has 
previously been shown to demonstrate stable gene expression in human 
epithelial cells treated with lithium (Nemeth et al., 2002) and has also previously 
been used for normalization in human placental cells treated with the drug 
(Roberts et al., 2007). ATB5B, a gene which encodes a protein involved in 
catalyzing ATP formation has previously been shown to be one of the most 
stable genes in cells treated with antidepressants (Sugden et al., 2010). ATB5B, 
was further shown to be the most stable reference gene in LCLs treated with 
lithium chronically along with CYC1 (see Figure 3B). The greatest variation in 
expression and therefore worst reference genes in LCLs treated acutely with 
lithium were observed in the genes SDHA and 18S (see Figure 2B and Table 1), 
and in SDHA and ACTB in LCLs treated chronically with lithium.  
  Previous research on the effects of antidepressants revealed that duration 
of drug treatment had little effect on housekeeping gene expression stability 
(Sugden et al., 2010). Here, we tested whether duration of treatment with a 
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mood-stabilizer might affect housekeeping gene expression. We observed the 
effects of a chronic (7 day) administration of lithium on housekeeping gene 
expression in LCLs, and compared it to an acute 24 hour treatment of lithium. 
The stability of genes in LCLs treated chronically showed a similar trend to the 
relative stability of genes in LCLs treated acutely. However, there were two genes 
which were key exceptions. In the chronically treated cells GAPDH became less 
stable and B2M became more stable (see Figure 4). Subsequently, GAPDH may 
be the most stable reference gene in LCLs treated acutely with lithium, but it is 
less suitable for LCLs treated chronically with the drug. If comparisons were to 
be drawn across different drug duration groups, ATP5B and UBC would in fact 
be considered two of the most stable reference genes (see Figure 4). These 
results consequently suggest that careful consideration is needed for the selection 
of reference genes not only for mood-stabilizer type but also for treatment 
duration.   
 To conclude, this is the first study to investigate the differential effects of 
mood-stabilizers on housekeeping gene expression in human cells from mood 
disorder patients. The study revealed that lithium and sodium valproate caused 
drug-specific effects on housekeeping gene expression stability, with lithium 
treatment duration also having some influences on housekeeping gene stability, 
particularly in the genes GAPDH and B2M. ACTB and RPL13A were the two 
most stable genes in LCLs treated acutely with sodium valproate, whereas 
GAPDH and ATP5B were the two most stable genes in LCLs treated acutely 
with lithium, and ATB5B and CYC1 were the two most stable genes in LCLs 
treated chronically with lithium. SDHA was amongst the most variably expressed 
housekeeping genes across all drug groups and as such may be considered an 
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unsuitable reference gene in in vitro experiments investigating the effects of 
mood-stabilizers. The use of mood-disorder patient derived LCLs in this study 
arguably means results from this in vitro experiment might not only extrapolate 
to other in vitro studies investigating the effects of mood-stabilizers but also to ex 
vivo studies investigating gene expression in lymphocytes extracted from mood 
disorder patients; although this would need to be confirmed in future studies. 
The study provides further evidence to a growing literature that the selection of 
appropriate housekeeping genes is important for the accurate normalization of 
target gene expression in experiments investigating the molecular effects of mood 
disorder pharmacotherapies. 
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S1: Cell  culture method 
The transformation of the B-lymphocyte component within the peripheral blood 
lymphocyte (PBL) population was performed through the culture of PBLs in a 
tissue culture medium infected with EBV supernatant, producing B 
lymphoblastoid cell lines. All cell lines were screened for mycoplasma 
contamination by PCR at ECACC. The human B lymphoblastoid cell lines were 
grown in suspension in 75 cm2 tissue culture flasks containing RPMI-1640 
medium (Sigma catalogue number R0883) supplemented with 10% foetal bovine 
serum, 2 mM L-glutamine, 100 units/mL penicillin, 0.1 mg/mL streptomycin and 
0.05 mg/mL neomycin at 37°C in a humidified atmosphere containing 5% CO2. 
All medium components were obtained from Sigma-Aldrich. 
 
S2: Acute drug treatment of LCLs 
 The five LCLs were subcultured at 3 x 105 cells/mL and seeded into 6-well 
plates, using 2 mL of cells per well. In the initial stage, seeded samples were 
incubated for 72 hours at 37°C in a humidified atmosphere containing 5% CO2. 
In the 24-hour serum-starve phase: Following the growth phase, the samples were 
quantified and transferred to fresh 2 mL centrifuge tubes. The tubes were 
centrifuged for 2000 g for 5 minutes, following which the medium was aspirated 
to obtain cell pellets. The cell pellets were resuspended in 2 mL of fresh growth 
medium containing 0.1% Foetal Bovine Serum (FBS), reseeded in fresh 6-well 
plates, and incubated for 24 hours at 37°C in a humidified atmosphere 
containing 5% CO2. The next stage was the 24-hour lithium or sodium valproate 
administration: Each sample was then transferred to a fresh 2 mL centrifuge tube 
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and cell pellets were obtained as above through centrifugation followed by 
aspiration of medium. The cells were resuspended in 2 mL of serum-free 
medium containing either a drug dilution or vehicle control reseeded in fresh 6-
well plates and incubated for 24 hours as above. Lastly was the 24-hour recovery 
phase: Following the treatment phase, the samples were transferred to a fresh 2 
mL centrifuge tube and cell pellets were obtained as above. The cells were 
resuspended in 2 mL of growth media containing full-serum (10%) FBS, then 
transferred to fresh 6-well plates and incubated for 24 hours as above. After the 
final 24 hour recovery phase, cell pellets were obtained as above, and these were 
immediately stored at -80°C for future RNA extraction. 
 
S3: Chronic Lithium Treatment in LCLs 
The samples were quantified and transferred to fresh 2 mL centrifuge tubes. The 
tubes were centrifuged and aspirated to obtain cell pellets, and the cells were 
resuspended in 2 mL of full-serum (10% FBS) growth medium containing either 
a drug or control dilution. The samples were then transferred to fresh 6-well 
plates, and incubated for 2 days as above. This was repeated twice more over the 
following 4 days. The samples were then transferred to fresh 2 mL centrifuge 
tubes and cell pellets were obtained as above. The cells were resuspended in 2 
mL of serum-free growth medium containing either a drug or control dilution, 
reseeded in fresh 6-well plates, and incubated for a further 24 hours. Following 
the treatment phase, cell pellets were obtained as above and were immediately 





Name Accession No. 
               
Anchor      
Nucleotide 
                      
Context length 
sequence (bp) 
ACTB NM_001101 1195 106 
GAPDH NM_002046 1087 142 
UBC NM_021009 452 192 
B2M NM_004048 362 141 
YWHAZ NM_003406 2585 150 
RPL13A NM_012423 727 223 
18S  M10098 235 99 
CYC1 NM_001916 929 207 
EIF4A2 NM_001967 900 146 
SDHA NM_004168 1032 154 
TOP1 NM_003286 2361 195 
ATP5B NM_001686 1200 150 
 
S4: Additional information on primers used, including accession number, anchor 




S5: Calculation of the optimum number of reference genes required for accurate 
normalization in LCLs treated with 0–0.6 mM sodium valproate for 24 hours. 



















S6: Calculation of the optimum number of reference genes required for accurate 
normalization in LCLs treated with 0–5 mM lithium for 24 hours. All 













S7: Calculation of the optimum number of reference genes required for accurate 
normalization in LCLs treated with 0–5 mM lithium for 7 days. All comparisons 













Genes geNorm Normfinder Bestkeeper ΔCt RefFinder 
ACTB 0.097 0.058 0.416 0.26 1.32 
RPL13A 0.097 0.065 0.397 0.26 1.68 
GAPDH 0.117 0.093 0.431 0.26 3.66 
TOP1 0.143 0.078 0.43 0.27 3.72 
B2M 0.166 0.164 0.492 0.29 5.23 
18S 0.34 0.507 0.16 0.55 6.04 
UBC 0.185 0.198 0.524 0.3 6.45 
YWHAZ 0.201 0.206 0.532 0.32 7.45 
ATP5B 0.217 0.231 0.506 0.33 7.74 
SDHA 0.248 0.329 0.588 0.4 9.24 




S8: Relative gene expression stability values for each of the 11 housekeeping 
genes found in LCLs treated acutely with sodium valproate. Results are based on 













Genes geNorm Normfinder Bestkeeper ΔCt RefFinder 
GAPDH 0.153 0.024 0.988 0.33 2 
ATP5B 0.128 0.165 1.037 0.34 2.63 
UBC 0.223 0.154 0.874 0.37 2.91 
CYC1 0.128 0.22 0.997 0.36 3.35 
YWHAZ 0.143 0.181 0.988 0.36 4.16 
RPL13A 0.197 0.193 1.055 0.36 5.62 
TOP1 0.237 0.246 0.962 0.38 5.86 
B2M 0.279 0.324 0.902 0.44 6.34 
ACTB 0.257 0.213 1.017 0.42 7.2 
SDHA 0.297 0.321 1.064 0.45 9.49 




S9: Relative gene expression stability values for each of the 11 housekeeping 
genes found in LCLs treated acutely with lithium. Results are based on geNorm, 














Genes geNorm Normfinder Bestkeeper ΔCt RefFinder 
ATP5B 0.215 0.102 0.405 0.54 1.78 
CYC1 0.252 0.096 0.403 0.55 2.63 
B2M 0.221 0.277 0.314 0.59 3.13 
UBC 0.232 0.246 0.398 0.59 3.46 
YWHAZ 0.215 0.275 0.451 0.61 4.43 
TOP1 0.278 0.248 0.383 0.6 4.53 
GAPDH 0.29 0.184 0.427 0.59 5.18 
RPC 0.244 0.276 0.427 0.6 6.44 
18S 0.353 0.443 0.499 0.77 9 
SDHA 0.533 1.249 0.705 1.37 10 




S10: Relative gene expression stability values for each of the 11 housekeeping 
genes found in LCLs treated chronically with lithium. Results are based on 

























Gene$Family Gene Sum$of$Squares df Mean$Square F Sig. ηp2
Complement C3 Between$Groups 3.557 2 1.779 1.188 0.311 0.032
Within$Groups 107.819 72 1.497
Total 111.376 74
C4A Between$Groups 3.441 2 1.721 1.008 0.369 0.023
Within$Groups 146.837 86 1.707
Total 150.278 88
C5 Between$Groups 1.897 2 0.948 1.457 0.239 0.034
Within$Groups 54.67 84 0.651
Total 56.566 86
Chemokine CCL2 Between$Groups 5.537 2 2.769 1.731 0.183 0.039
Within$Groups 137.524 86 1.599
Total 143.061 88
CCL3 Between$Groups 0.267 2 0.133 0.215 0.807 0.005
Within$Groups 53.902 87 0.62
Total 54.168 89
CCL4 Between$Groups 2.616 2 1.308 1.93 0.151 0.042
Within$Groups 58.961 87 0.678
Total 61.578 89
CCL5 Between$Groups 0.488 2 0.244 0.309 0.735 0.007
Within$Groups 67.852 86 0.789
Total 68.34 88
CCL8 Between$Groups 2.333 2 1.167 0.697 0.502 0.022
Within$Groups 105.472 63 1.674
Total 107.806 65
CCL16 Between$Groups 3.178 2 1.589 1.533 0.222 0.036
Within$Groups 85.024 82 1.037
Total 88.202 84
CCL18 Between$Groups 1.858 2 0.929 0.724 0.491 0.036
Within$Groups 50.038 39 1.283
Total 51.896 41
CCL19 Between$Groups 29.083 2 14.542 1.36 0.264 0.041
Within$Groups 673.417 63 10.689
Total 702.5 65
CCL20 Between$Groups 11.932 2 5.966 1.011 0.369 0.027
Within$Groups 436.873 74 5.904
Total 448.805 76
CCL23 Between$Groups 6.46 2 3.23 1.786 0.174 0.040
Within$Groups 153.678 85 1.808
Total 160.138 87
CCL24 Between$Groups 10.613 2 5.306 6.586 0.002 0.134
Within$Groups 68.487 85 0.806
Total 79.1 87
CCL25 Between$Groups 11.433 2 5.716 1.248 0.292 0.029
Within$Groups 389.445 85 4.582
Total 400.878 87
CCL26 Between$Groups 10.465 2 5.233 0.645 0.53 0.031
Within$Groups 324.311 40 8.108
Total 334.776 42
CXCL1 Between$Groups 8.18 2 4.09 3.727 0.028 0.079
Within$Groups 95.478 87 1.097
Total 103.658 89
CXCL2 Between$Groups 0.622 2 0.311 0.084 0.919 0.002
Within$Groups 295.105 80 3.689
Total 295.727 82
CXCL3 Between$Groups 2.899 2 1.45 1.142 0.325 0.032
Within$Groups 86.327 68 1.27
Total 89.226 70
CXCL5 Between$Groups 1.818 2 0.909 0.552 0.578 0.013
Within$Groups 143.337 87 1.648
Total 145.155 89
CXCL6 Between$Groups 15.262 2 7.631 4.378 0.015 0.091
Within$Groups 151.652 87 1.743
Total 166.914 89
CXCL9 Between$Groups 14.887 2 7.444 5.093 0.008 0.107
Within$Groups 124.219 85 1.461
Total 139.107 87
CXCL10 Between$Groups 20.919 2 10.46 4.51 0.014 0.095
Within$Groups 199.454 86 2.319
Total 220.374 88
CXCL11 Between$Groups 1.485 2 0.743 0.407 0.667 0.015
Within$Groups 96.611 53 1.823
Total 98.096 55
CXCL12 Between$Groups 0.363 2 0.182 0.185 0.832 0.010
Within$Groups 34.364 35 0.982
Total 34.728 37
CXCL13 Between$Groups 0.387 2 0.194 0.157 0.855 0.005
Within$Groups 85.118 69 1.234
Total 85.506 71
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Gene$Family Gene Sum$of$Squares df Mean$Square F Sig. ηp2
Chemokine$Receptor CCR1 Between$Groups 3.02 2 1.51 1.988 0.143 0.044
Within$Groups 66.064 87 0.759
Total 69.084 89
CCR2 Between$Groups 3.193 2 1.597 1.094 0.339 0.025
Within$Groups 126.935 87 1.459
Total 130.128 89
CCR3 Between$Groups 1.982 2 0.991 0.502 0.607 0.011
Within$Groups 171.702 87 1.974
Total 173.684 89
CCR4 Between$Groups 6.477 2 3.238 3.28 0.042 0.070
Within$Groups 85.886 87 0.987
Total 92.363 89
CCR5 Between$Groups 0.472 2 0.236 0.225 0.799 0.005
Within$Groups 91.486 87 1.052
Total 91.958 89
CCR6 Between$Groups 4.438 2 2.219 3.548 0.033 0.075
Within$Groups 54.405 87 0.625
Total 58.843 89
CCR7 Between$Groups 4.678 2 2.339 2.759 0.069 0.060
Within$Groups 73.752 87 0.848
Total 78.43 89
CCR8 Between$Groups 3.23 2 1.615 0.569 0.568 0.013
Within$Groups 247.13 87 2.841
Total 250.36 89
CCR9 Between$Groups 6.269 2 3.135 3.334 0.04 0.071
Within$Groups 81.802 87 0.94
Total 88.071 89
CX3CR1 Between$Groups 1.501 2 0.751 0.489 0.615 0.011
Within$Groups 133.396 87 1.533
Total 134.897 89
XCR1 Between$Groups 10.489 2 5.245 6.332 0.003 0.127
Within$Groups 72.061 87 0.828
Total 82.55 89
Interleukin IL1A Between$Groups 2.967 2 1.484 0.579 0.563 0.017
Within$Groups 176.663 69 2.56
Total 179.63 71
IL1B Between$Groups 3.541 2 1.771 1.775 0.176 0.039
Within$Groups 86.781 87 0.997
Total 90.322 89
IL5 Between$Groups 2.456 2 1.228 0.588 0.558 0.013
Within$Groups 179.571 86 2.088
Total 182.027 88
IL6 Between$Groups 5.592 2 2.796 1.98 0.145 0.046
Within$Groups 117.242 83 1.413
Total 122.834 85
IL8 Between$Groups 20.326 2 10.163 6.872 0.002 0.136
Within$Groups 128.665 87 1.479
Total 148.991 89
IL11 Between$Groups 3.197 2 1.598 0.781 0.464 0.031
Within$Groups 100.336 49 2.048
Total 103.533 51
IL10 Between$Groups 4.081 2 2.04 1.593 0.209 0.035
Within$Groups 111.444 87 1.281
Total 115.524 89
IL13 Between$Groups 12.508 2 6.254 1.545 0.222 0.052
Within$Groups 226.643 56 4.047
Total 239.151 58
IL17C Between$Groups 0.536 2 0.268 0.274 0.761 0.006
Within$Groups 85 87 0.977
Total 85.536 89
IL22 Between$Groups 2.815 2 1.408 1.064 0.351 0.031
Within$Groups 88.624 67 1.323
Total 91.439 69
IL36A Between$Groups 0.004 2 0.002 0.002 0.998 0.000
Within$Groups 86.904 77 1.129
Total 86.908 79
IL37 Between$Groups 4.43 2 2.215 1.136 0.326 0.027
Within$Groups 159.819 82 1.949




Gene$Family Gene Sum$of$Squares df Mean$Square F Sig. ηp2
Interleukin$receptor IL1R1 Between$Groups 0.209 2 0.105 0.082 0.921 0.002
Within$Groups 111.086 87 1.277
Total 111.295 89
IL1RN Between$Groups 1.044 2 0.522 0.662 0.518 0.015
Within$Groups 68.538 87 0.788
Total 69.582 89
IL5RA Between$Groups 4.096 2 2.048 1.863 0.161 0.041
Within$Groups 95.653 87 1.099
Total 99.749 89
IL8RA Between$Groups 1.705 2 0.852 1.039 0.358 0.023
Within$Groups 71.414 87 0.821
Total 73.119 89
IL8RB Between$Groups 2.343 2 1.171 1.16 0.318 0.026
Within$Groups 87.86 87 1.01
Total 90.203 89
IL9R Between$Groups 2.956 2 1.478 0.989 0.381 0.047
Within$Groups 59.756 40 1.494
Total 62.712 42
IL10RA Between$Groups 1.026 2 0.513 1.066 0.349 0.024
Within$Groups 41.861 87 0.481
Total 42.887 89
IL10RB Between$Groups 0.562 2 0.281 0.33 0.72 0.008
Within$Groups 74.094 87 0.852
Total 74.656 89
IL13RA1 Between$Groups 0.824 2 0.412 0.571 0.567 0.013
Within$Groups 62.808 87 0.722
Total 63.632 89
Tumor$Necrosis$Factor TNF Between$Groups 0.701 2 0.35 1.036 0.359 0.023
Within$Groups 29.425 87 0.338
Total 30.126 89
LTA Between$Groups 1.309 2 0.655 1.036 0.359 0.023
Within$Groups 54.952 87 0.632
Total 56.261 89
LTB Between$Groups 1.108 2 0.554 0.824 0.442 0.019
Within$Groups 58.495 87 0.672
Total 59.604 89
CD40LG Between$Groups 0.321 2 0.161 0.425 0.655 0.010
Within$Groups 32.926 87 0.378
Total 33.247 89
LTB4R Between$Groups 4.044 2 2.022 2.249 0.112 0.049
Within$Groups 78.201 87 0.899
Total 82.244 89
Other$ BCL6 Between$Groups 2.034 2 1.017 1.064 0.35 0.024
Within$Groups 82.208 86 0.956
Total 84.243 88
AIMP1 Between$Groups 1.735 2 0.868 0.942 0.394 0.021
Within$Groups 80.118 87 0.921
Total 81.853 89
CEBPB Between$Groups 2.111 2 1.055 0.865 0.424 0.020
Within$Groups 106.101 87 1.22
Total 108.212 89
MIF Between$Groups 1.863 2 0.931 1.387 0.255 0.031
Within$Groups 58.406 87 0.671
Total 60.269 89
NR3C1 Between$Groups 4.622 2 2.311 3.465 0.036 0.074
Within$Groups 58.029 87 0.667
Total 62.651 89
SPP1 Between$Groups 13.166 2 6.583 1.937 0.15 0.043
Within$Groups 292.239 86 3.398
Total 305.404 88
TOLLIP Between$Groups 0.346 2 0.173 0.54 0.584 0.012
Within$Groups 27.869 87 0.32





Appendix B: Games-Howell Results (Chapter 3)  
 
 
Gene$Family Gene Subject$Group Comparison$Group Mean$Difference S.E. Sig.
Lower$Bound Upper$Bound
Complement C3 Control MDD B0.529 0.384 0.360 B1.458 0.400
BPD B0.419 0.299 0.351 B1.148 0.311
MDD Control 0.529 0.384 0.360 B0.400 1.458
BPD 0.110 0.344 0.945 B0.725 0.945
BPD Control 0.419 0.299 0.351 B0.311 1.148
MDD B0.110 0.344 0.945 B0.945 0.725
C4A Control MDD B0.475 0.355 0.380 B1.330 0.379
BPD B0.316 0.340 0.624 B1.135 0.503
MDD Control 0.475 0.355 0.380 B0.379 1.330
BPD 0.159 0.324 0.876 B0.621 0.939
BPD Control 0.316 0.340 0.624 B0.503 1.135
MDD B0.159 0.324 0.876 B0.939 0.621
C5 Control MDD 0.007 0.224 0.999 B0.532 0.546
BPD B0.312 0.200 0.272 B0.795 0.170
MDD Control B0.007 0.224 0.999 B0.546 0.532
BPD B0.319 0.207 0.279 B0.818 0.179
BPD Control 0.312 0.200 0.272 B0.170 0.795
MDD 0.319 0.207 0.279 B0.179 0.818
CCL2 Control MDD B0.449 0.292 0.283 B1.154 0.256
BPD B0.588 0.363 0.247 B1.462 0.287
MDD Control 0.449 0.292 0.283 B0.256 1.154
BPD B0.139 0.326 0.905 B0.927 0.649
BPD Control 0.588 0.363 0.247 B0.287 1.462
MDD 0.139 0.326 0.905 B0.649 0.927
CCL3 Control MDD B0.112 0.209 0.855 B0.615 0.392
BPD B0.119 0.191 0.809 B0.579 0.342
MDD Control 0.112 0.209 0.855 B0.392 0.615
BPD B0.007 0.209 0.999 B0.509 0.495
BPD Control 0.119 0.191 0.809 B0.342 0.579
MDD 0.007 0.209 0.999 B0.495 0.509
CCL4 Control MDD B0.166 0.211 0.712 B0.674 0.341
BPD B0.415 0.223 0.159 B0.951 0.121
MDD Control 0.166 0.211 0.712 B0.341 0.674
BPD B0.249 0.204 0.445 B0.739 0.241
BPD Control 0.415 0.223 0.159 B0.121 0.951
MDD 0.249 0.204 0.445 B0.241 0.739
CCL5 Control MDD 0.033 0.244 0.990 B0.554 0.621
BPD B0.137 0.232 0.825 B0.695 0.421
MDD Control B0.033 0.244 0.990 B0.621 0.554
BPD B0.170 0.217 0.714 B0.693 0.352
BPD Control 0.137 0.232 0.825 B0.421 0.695
MDD 0.170 0.217 0.714 B0.352 0.693
CCL8 Control MDD B0.363 0.412 0.655 B1.372 0.646
BPD 0.073 0.337 0.975 B0.747 0.892
MDD Control 0.363 0.412 0.655 B0.646 1.372
BPD 0.436 0.431 0.575 B0.617 1.489
BPD Control B0.073 0.337 0.975 B0.892 0.747
MDD B0.436 0.431 0.575 B1.489 0.617
CCL16 Control MDD B0.291 0.266 0.522 B0.934 0.351
BPD B0.475 0.288 0.235 B1.170 0.220
MDD Control 0.291 0.266 0.522 B0.351 0.934
BPD B0.183 0.259 0.760 B0.809 0.443
BPD Control 0.475 0.288 0.235 B0.220 1.170









Gene$Family Gene Subject$Group Comparison$Group Mean$Difference S.E. Sig.
Lower$Bound Upper$Bound
CCL18 Control MDD 0.206 0.419 0.877 I0.903 1.314
BPD 0.474 0.403 0.478 I0.532 1.481
MDD Control I0.206 0.419 0.877 I1.314 0.903
BPD 0.269 0.508 0.858 I1.016 1.553
BPD Control I0.474 0.403 0.478 I1.481 0.532
MDD I0.269 0.508 0.858 I1.553 1.016
CCL19 Control MDD 1.544 1.095 0.351 I1.181 4.268
BPD 0.503 0.324 0.279 I0.287 1.293
MDD Control I1.544 1.095 0.351 I4.268 1.181
BPD I1.041 1.085 0.609 I3.745 1.664
BPD Control I0.503 0.324 0.279 I1.293 0.287
MDD 1.041 1.085 0.609 I1.664 3.745
CCL20 Control MDD 0.645 0.760 0.676 I1.230 2.520
BPD I0.295 0.316 0.622 I1.060 0.470
MDD Control I0.645 0.760 0.676 I2.520 1.230
BPD I0.940 0.774 0.453 I2.842 0.962
BPD Control 0.295 0.316 0.622 I0.470 1.060
MDD 0.940 0.774 0.453 I0.962 2.842
CCL23 Control MDD I0.235 0.360 0.792 I1.102 0.632
BPD 0.419 0.344 0.447 I0.409 1.248
MDD Control 0.235 0.360 0.792 I0.632 1.102
BPD 0.654 0.348 0.153 I0.182 1.491
BPD Control I0.419 0.344 0.447 I1.248 0.409
MDD I0.654 0.348 0.153 I1.491 0.182
CCL24 Control MDD 0.779 0.259 0.011 0.153 1.404
BPD 0.102 0.181 0.839 I0.334 0.538
MDD Control I0.779 0.259 0.011 I1.404 I0.153
BPD I0.676 0.249 0.025 I1.280 I0.072
BPD Control I0.102 0.181 0.839 I0.538 0.334
MDD 0.676 0.249 0.025 0.072 1.280
CCL25 Control MDD 0.130 0.537 0.968 I1.162 1.423
BPD I0.692 0.560 0.438 I2.042 0.658
MDD Control I0.130 0.537 0.968 I1.423 1.162
BPD I0.822 0.579 0.337 I2.215 0.570
BPD Control 0.692 0.560 0.438 I0.658 2.042
MDD 0.822 0.579 0.337 I0.570 2.215
CCL26 Control MDD I0.992 1.481 0.785 I4.945 2.961
BPD I1.272 1.476 0.674 I5.220 2.676
MDD Control 0.992 1.481 0.785 I2.961 4.945
BPD I0.280 0.406 0.772 I1.292 0.732
BPD Control 1.272 1.476 0.674 I2.676 5.220
MDD 0.280 0.406 0.772 I0.732 1.292
CXCL1 Control MDD I0.738 0.261 0.017 I1.366 I0.111
BPD I0.385 0.274 0.345 I1.045 0.274
MDD Control 0.738 0.261 0.017 0.111 1.366
BPD 0.353 0.276 0.413 I0.311 1.017
BPD Control 0.385 0.274 0.345 I0.274 1.045
MDD I0.353 0.276 0.413 I1.017 0.311
CXCL2 Control MDD I0.202 0.586 0.937 I1.642 1.237
BPD I0.150 0.329 0.892 I0.945 0.645
MDD Control 0.202 0.586 0.937 I1.237 1.642
BPD 0.053 0.614 0.996 I1.447 1.552
BPD Control 0.150 0.329 0.892 I0.645 0.945










Gene$Family Gene Subject$Group Comparison$Group Mean$Difference S.E. Sig.
Lower$Bound Upper$Bound
CXCL3 Control MDD 0.270 0.322 0.680 H0.509 1.049
BPD H0.250 0.328 0.727 H1.042 0.542
MDD Control H0.270 0.322 0.680 H1.049 0.509
BPD H0.520 0.314 0.233 H1.284 0.243
BPD Control 0.250 0.328 0.727 H0.542 1.042
MDD 0.520 0.314 0.233 H0.243 1.284
CXCL5 Control MDD H0.227 0.327 0.768 H1.013 0.560
BPD 0.116 0.336 0.937 H0.692 0.923
MDD Control 0.227 0.327 0.768 H0.560 1.013
BPD 0.342 0.331 0.560 H0.455 1.139
BPD Control H0.116 0.336 0.937 H0.923 0.692
MDD H0.342 0.331 0.560 H1.139 0.455
CXCL6 Control MDD H1.007 0.347 0.015 H1.848 H0.167
BPD H0.459 0.294 0.270 H1.166 0.248
MDD Control 1.007 0.347 0.015 0.167 1.848
BPD 0.549 0.377 0.319 H0.358 1.456
BPD Control 0.459 0.294 0.270 H0.248 1.166
MDD H0.549 0.377 0.319 H1.456 0.358
CXCL9 Control MDD H0.517 0.347 0.303 H1.352 0.318
BPD 0.487 0.274 0.187 H0.174 1.149
MDD Control 0.517 0.347 0.303 H0.318 1.352
BPD 1.004 0.317 0.007 0.239 1.770
BPD Control H0.487 0.274 0.187 H1.149 0.174
MDD H1.004 0.317 0.007 H1.770 H0.239
CXCL10 Control MDD H1.094 0.372 0.013 H1.991 H0.197
BPD H0.150 0.388 0.921 H1.084 0.784
MDD Control 1.094 0.372 0.013 0.197 1.991
BPD 0.944 0.421 0.072 H0.068 1.956
BPD Control 0.150 0.388 0.921 H0.784 1.084
MDD H0.944 0.421 0.072 H1.956 0.068
CXCL11 Control MDD H0.008 0.444 1.000 H1.102 1.086
BPD 0.328 0.434 0.733 H0.731 1.386
MDD Control 0.008 0.444 1.000 H1.086 1.102
BPD 0.336 0.430 0.718 H0.721 1.393
BPD Control H0.328 0.434 0.733 H1.386 0.731
MDD H0.336 0.430 0.718 H1.393 0.721
CXCL12 Control MDD 0.012 0.342 0.999 H0.857 0.880
BPD H0.197 0.430 0.892 H1.270 0.877
MDD Control H0.012 0.342 0.999 H0.880 0.857
BPD H0.208 0.374 0.844 H1.153 0.736
BPD Control 0.197 0.430 0.892 H0.877 1.270
MDD 0.208 0.374 0.844 H0.736 1.153
CXCL13 Control MDD H0.173 0.316 0.849 H0.937 0.592
BPD H0.106 0.316 0.940 H0.874 0.661
MDD Control 0.173 0.316 0.849 H0.592 0.937
BPD 0.066 0.329 0.978 H0.733 0.865
BPD Control 0.106 0.316 0.940 H0.661 0.874
MDD H0.066 0.329 0.978 H0.865 0.733
Chemokine$receptor CCR1 Control MDD H0.392 0.227 0.202 H0.938 0.153
BPD H0.385 0.216 0.184 H0.903 0.134
MDD Control 0.392 0.227 0.202 H0.153 0.938
BPD 0.008 0.233 0.999 H0.552 0.567
BPD Control 0.385 0.216 0.184 H0.134 0.903










CCR2 Control MDD +0.204 0.261 0.717 +0.832 0.424
BPD +0.460 0.337 0.366 +1.274 0.353
MDD Control 0.204 0.261 0.717 +0.424 0.832
BPD +0.257 0.332 0.721 +1.058 0.544
BPD Control 0.460 0.337 0.366 +0.353 1.274
MDD 0.257 0.332 0.721 +0.544 1.058
CCR3 Control MDD +0.363 0.371 0.593 +1.257 0.530
BPD +0.181 0.373 0.878 +1.079 0.716
MDD Control 0.363 0.371 0.593 +0.530 1.257
BPD 0.182 0.343 0.857 +0.644 1.008
BPD Control 0.181 0.373 0.878 +0.716 1.079
MDD +0.182 0.343 0.857 +1.008 0.644
CCR4 Control MDD +0.615 0.255 0.049 +1.229 +0.001
BPD +0.108 0.236 0.891 +0.676 0.460
MDD Control 0.615 0.255 0.049 0.001 1.229
BPD 0.507 0.278 0.170 +0.161 1.175
BPD Control 0.108 0.236 0.891 +0.460 0.676
MDD +0.507 0.278 0.170 +1.175 0.161
CCR5 Control MDD +0.057 0.231 0.967 +0.614 0.500
BPD +0.174 0.291 0.822 +0.875 0.527
MDD Control 0.057 0.231 0.967 +0.500 0.614
BPD +0.117 0.269 0.900 +0.766 0.532
BPD Control 0.174 0.291 0.822 +0.527 0.875
MDD 0.117 0.269 0.900 +0.532 0.766
CCR6 Control MDD +0.510 0.192 0.028 +0.973 +0.047
BPD +0.419 0.205 0.111 +0.913 0.074
MDD Control 0.510 0.192 0.028 0.047 0.973
BPD 0.091 0.215 0.907 +0.426 0.607
BPD Control 0.419 0.205 0.111 +0.074 0.913
MDD +0.091 0.215 0.907 +0.607 0.426
CCR7 Control MDD +0.553 0.242 0.066 +1.136 0.030
BPD +0.345 0.213 0.247 +0.859 0.169
MDD Control 0.553 0.242 0.066 +0.030 1.136
BPD 0.208 0.256 0.697 +0.409 0.825
BPD Control 0.345 0.213 0.247 +0.169 0.859
MDD +0.208 0.256 0.697 +0.825 0.409
CCR8 Control MDD +0.402 0.486 0.689 +1.584 0.781
BPD 0.001 0.294 1.000 +0.707 0.708
MDD Control 0.402 0.486 0.689 +0.781 1.584
BPD 0.402 0.496 0.698 +0.802 1.606
BPD Control +0.001 0.294 1.000 +0.708 0.707
MDD +0.402 0.496 0.698 +1.606 0.802
CCR9 Control MDD +0.644 0.249 0.032 +1.242 +0.046
BPD +0.368 0.256 0.327 +0.983 0.247
MDD Control 0.644 0.249 0.032 0.046 1.242
BPD 0.276 0.247 0.507 +0.318 0.870
BPD Control 0.368 0.256 0.327 +0.247 0.983
MDD +0.276 0.247 0.507 +0.870 0.318
CX3CR1 Control MDD +0.280 0.314 0.648 +1.035 0.475
BPD +0.012 0.335 0.999 +0.817 0.793
MDD Control 0.280 0.314 0.648 +0.475 1.035
BPD 0.268 0.310 0.666 +0.479 1.014
BPD Control 0.012 0.335 0.999 +0.793 0.817








Gene$Family Gene Subject$Group Comparison$Group Mean$Difference S.E. Sig.
Lower$Bound Upper$Bound
XCR1 Control MDD 0.109 0.226 0.881 I0.438 0.656
BPD I0.664 0.214 0.009 I1.180 I0.148
MDD Control I0.109 0.226 0.881 I0.656 0.438
BPD I0.772 0.262 0.013 I1.404 I0.141
BPD Control 0.664 0.214 0.009 0.148 1.180
MDD 0.772 0.262 0.013 0.141 1.404
Interleukin IL1A Control MDD I0.410 0.455 0.642 I1.511 0.690
BPD I0.444 0.487 0.635 I1.625 0.737
MDD Control 0.410 0.455 0.642 I0.690 1.511
BPD I0.034 0.447 0.997 I1.121 1.053
BPD Control 0.444 0.487 0.635 I0.737 1.625
MDD 0.034 0.447 0.997 I1.053 1.121
IL1B Control MDD I0.469 0.246 0.147 I1.061 0.124
BPD I0.346 0.273 0.420 I1.003 0.311
MDD Control 0.469 0.246 0.147 I0.124 1.061
BPD 0.123 0.254 0.879 I0.488 0.733
BPD Control 0.346 0.273 0.420 I0.311 1.003
MDD I0.123 0.254 0.879 I0.733 0.488
IL5 Control MDD I0.405 0.400 0.573 I1.369 0.559
BPD I0.204 0.390 0.861 I1.145 0.737
MDD Control 0.405 0.400 0.573 I0.559 1.369
BPD 0.201 0.328 0.814 I0.588 0.990
BPD Control 0.204 0.390 0.861 I0.737 1.145
MDD I0.201 0.328 0.814 I0.990 0.588
IL6 Control MDD I0.589 0.328 0.180 I1.379 0.200
BPD I0.107 0.300 0.933 I0.829 0.616
MDD Control 0.589 0.328 0.180 I0.200 1.379
BPD 0.483 0.315 0.284 I0.277 1.243
BPD Control 0.107 0.300 0.933 I0.616 0.829
MDD I0.483 0.315 0.284 I1.243 0.277
IL8 Control MDD I1.021 0.303 0.004 I1.749 I0.292
BPD I0.995 0.316 0.007 I1.756 I0.234
MDD Control 1.021 0.303 0.004 0.292 1.749
BPD 0.026 0.323 0.997 I0.750 0.802
BPD Control 0.995 0.316 0.007 0.234 1.756
MDD I0.026 0.323 0.997 I0.802 0.750
IL10 Control MDD I0.432 0.314 0.362 I1.190 0.327
BPD 0.037 0.247 0.987 I0.556 0.631
MDD Control 0.432 0.314 0.362 I0.327 1.190
BPD 0.469 0.311 0.295 I0.281 1.220
BPD Control I0.037 0.247 0.987 I0.631 0.556
MDD I0.469 0.311 0.295 I1.220 0.281
IL11 Control MDD I0.029 0.433 0.998 I1.088 1.031
BPD I0.575 0.525 0.526 I1.887 0.737
MDD Control 0.029 0.433 0.998 I1.031 1.088
BPD I0.546 0.532 0.567 I1.868 0.775
BPD Control 0.575 0.525 0.526 I0.737 1.887
MDD 0.546 0.532 0.567 I0.775 1.868
IL13 Control MDD I0.071 0.369 0.980 I0.972 0.830
BPD 0.964 0.789 0.454 I1.028 2.955
MDD Control 0.071 0.369 0.980 I0.830 0.972
BPD 1.034 0.801 0.415 I0.980 3.049
BPD Control I0.964 0.789 0.454 I2.955 1.028











Gene$Family Gene Subject$Group Comparison$Group Mean$Difference S.E. Sig.
Lower$Bound Upper$Bound
IL17C Control MDD D0.018 0.235 0.997 D0.583 0.548
BPD D0.172 0.273 0.805 D0.828 0.485
MDD Control 0.018 0.235 0.997 D0.548 0.583
BPD D0.154 0.257 0.820 D0.773 0.464
BPD Control 0.172 0.273 0.805 D0.485 0.828
MDD 0.154 0.257 0.820 D0.464 0.773
IL22 Control MDD 0.168 0.331 0.868 D0.634 0.970
BPD D0.319 0.345 0.628 D1.155 0.517
MDD Control D0.168 0.331 0.868 D0.970 0.634
BPD D0.487 0.333 0.320 D1.295 0.322
BPD Control 0.319 0.345 0.628 D0.517 1.155
MDD 0.487 0.333 0.320 D0.322 1.295
IL36A Control MDD 0.009 0.325 1.000 D0.778 0.796
BPD 0.017 0.251 0.997 D0.589 0.623
MDD Control D0.009 0.325 1.000 D0.796 0.778
BPD 0.008 0.305 1.000 D0.734 0.750
BPD Control D0.017 0.251 0.997 D0.623 0.589
MDD D0.008 0.305 1.000 D0.750 0.734
IL37 Control MDD 0.304 0.339 0.646 D0.517 1.125
BPD D0.253 0.356 0.758 D1.113 0.607
MDD Control D0.304 0.339 0.646 D1.125 0.517
BPD D0.557 0.410 0.369 D1.544 0.430
BPD Control 0.253 0.356 0.758 D0.607 1.113
MDD 0.557 0.410 0.369 D0.430 1.544
Interleukin$receptor IL1R1 Control MDD D0.074 0.314 0.970 D0.828 0.681
BPD 0.043 0.266 0.986 D0.597 0.683
MDD Control 0.074 0.314 0.970 D0.681 0.828
BPD 0.117 0.294 0.917 D0.592 0.826
BPD Control D0.043 0.266 0.986 D0.683 0.597
MDD D0.117 0.294 0.917 D0.826 0.592
IL1RN Control MDD D0.206 0.230 0.645 D0.759 0.347
BPD D0.246 0.221 0.511 D0.778 0.287
MDD Control 0.206 0.230 0.645 D0.347 0.759
BPD D0.040 0.236 0.984 D0.608 0.528
BPD Control 0.246 0.221 0.511 D0.287 0.778
MDD 0.040 0.236 0.984 D0.528 0.608
IL5RA Control MDD D0.249 0.285 0.659 D0.935 0.437
BPD 0.273 0.255 0.536 D0.341 0.887
MDD Control 0.249 0.285 0.659 D0.437 0.935
BPD 0.522 0.271 0.140 D0.130 1.175
BPD Control D0.273 0.255 0.536 D0.887 0.341
MDD D0.522 0.271 0.140 D1.175 0.130
IL8RA Control MDD D0.123 0.224 0.846 D0.662 0.415
BPD D0.333 0.244 0.364 D0.920 0.253
MDD Control 0.123 0.224 0.846 D0.415 0.662
BPD D0.210 0.234 0.644 D0.773 0.353
BPD Control 0.333 0.244 0.364 D0.253 0.920
MDD 0.210 0.234 0.644 D0.353 0.773
IL8RB Control MDD D0.021 0.240 0.996 D0.598 0.556
BPD D0.352 0.272 0.404 D1.007 0.302
MDD Control 0.021 0.240 0.996 D0.556 0.598
BPD D0.331 0.266 0.431 D0.971 0.308
BPD Control 0.352 0.272 0.404 D0.302 1.007










Gene$Family Gene Subject$Group Comparison$Group Mean$Difference S.E. Sig.
Lower$Bound Upper$Bound
IL9R Control MDD 0.173 0.487 0.933 J1.061 1.407
BPD J0.437 0.319 0.371 J1.231 0.356
MDD Control J0.173 0.487 0.933 J1.407 1.061
BPD J0.611 0.502 0.456 J1.873 0.652
BPD Control 0.437 0.319 0.371 J0.356 1.231
MDD 0.611 0.502 0.456 J0.652 1.873
IL10RA Control MDD J0.205 0.165 0.433 J0.603 0.192
BPD J0.243 0.183 0.388 J0.685 0.199
MDD Control 0.205 0.165 0.433 J0.192 0.603
BPD J0.038 0.188 0.978 J0.490 0.415
BPD Control 0.243 0.183 0.388 J0.199 0.685
MDD 0.038 0.188 0.978 J0.415 0.490
IL10RB Control MDD J0.187 0.218 0.668 J0.713 0.338
BPD J0.136 0.236 0.835 J0.706 0.435
MDD Control 0.187 0.218 0.668 J0.338 0.713
BPD 0.052 0.259 0.978 J0.571 0.674
BPD Control 0.136 0.236 0.835 J0.435 0.706
MDD J0.052 0.259 0.978 J0.674 0.571
IL13RA1 Control MDD J0.211 0.210 0.575 J0.716 0.293
BPD J0.193 0.221 0.657 J0.724 0.337
MDD Control 0.211 0.210 0.575 J0.293 0.716
BPD 0.018 0.228 0.997 J0.530 0.566
BPD Control 0.193 0.221 0.657 J0.337 0.724
MDD J0.018 0.228 0.997 J0.566 0.530
Tumor$necrosis$factor TNF Control MDD J0.023 0.154 0.987 J0.397 0.351
BPD J0.198 0.168 0.474 J0.604 0.208
MDD Control 0.023 0.154 0.987 J0.351 0.397
BPD J0.174 0.124 0.347 J0.474 0.125
BPD Control 0.198 0.168 0.474 J0.208 0.604
MDD 0.174 0.124 0.347 J0.125 0.474
LTA Control MDD J0.183 0.191 0.608 J0.644 0.279
BPD J0.292 0.230 0.416 J0.845 0.260
MDD Control 0.183 0.191 0.608 J0.279 0.644
BPD J0.110 0.192 0.836 J0.575 0.355
BPD Control 0.292 0.230 0.416 J0.260 0.845
MDD 0.110 0.192 0.836 J0.355 0.575
LTB Control MDD J0.130 0.190 0.775 J0.589 0.330
BPD J0.272 0.239 0.496 J0.847 0.304
MDD Control 0.130 0.190 0.775 J0.330 0.589
BPD J0.142 0.203 0.764 J0.633 0.349
BPD Control 0.272 0.239 0.496 J0.304 0.847
CD40LG Control MDD 0.010 0.150 0.998 J0.352 0.372
BPD J0.122 0.170 0.755 J0.530 0.287
MDD Control J0.010 0.150 0.998 J0.372 0.352
BPD J0.131 0.156 0.677 J0.507 0.244
BPD Control 0.122 0.170 0.755 J0.287 0.530
MDD 0.131 0.156 0.677 J0.244 0.507
LTB4R Control MDD J0.359 0.235 0.289 J0.930 0.212
BPD J0.504 0.279 0.177 J1.176 0.168
MDD Control 0.359 0.235 0.289 J0.212 0.930
BPD J0.145 0.215 0.779 J0.666 0.376
BPD Control 0.504 0.279 0.177 J0.168 1.176











Gene$Family Gene Subject$Group Comparison$Group Mean$Difference S.E. Sig.
Lower$Bound Upper$Bound
Other AIMP1 Control MDD G0.298 0.192 0.277 G0.761 0.165
BPD G0.291 0.276 0.546 G0.959 0.376
MDD Control 0.298 0.192 0.277 G0.165 0.761
BPD 0.006 0.266 1.000 G0.640 0.652
BPD Control 0.291 0.276 0.546 G0.376 0.959
MDD G0.006 0.266 1.000 G0.652 0.640
BCL6 Control MDD G0.158 0.274 0.833 G0.818 0.501
BPD G0.370 0.258 0.330 G0.993 0.252
MDD Control 0.158 0.274 0.833 G0.501 0.818
BPD G0.212 0.224 0.614 G0.753 0.328
BPD Control 0.370 0.258 0.330 G0.252 0.993
MDD 0.212 0.224 0.614 G0.328 0.753
CEBPB Control MDD G0.213 0.283 0.734 G0.894 0.469
BPD 0.161 0.291 0.845 G0.540 0.862
MDD Control 0.213 0.283 0.734 G0.469 0.894
BPD 0.374 0.281 0.383 G0.301 1.049
BPD Control G0.161 0.291 0.845 G0.862 0.540
MDD G0.374 0.281 0.383 G1.049 0.301
MIF Control MDD G0.233 0.191 0.451 G0.697 0.232
BPD G0.346 0.245 0.341 G0.934 0.243
MDD Control 0.233 0.191 0.451 G0.232 0.697
BPD G0.113 0.194 0.831 G0.585 0.359
BPD Control 0.346 0.245 0.341 G0.243 0.934
MDD 0.113 0.194 0.831 G0.359 0.585
NR3C1 Control MDD G0.543 0.202 0.025 G1.028 G0.057
BPD G0.373 0.222 0.221 G0.906 0.161
MDD Control 0.543 0.202 0.025 0.057 1.028
BPD 0.170 0.208 0.696 G0.332 0.672
BPD Control 0.373 0.222 0.221 G0.161 0.906
MDD G0.170 0.208 0.696 G0.672 0.332
SPP1 Control MDD 0.537 0.476 0.502 G0.610 1.684
BPD G0.405 0.500 0.697 G1.607 0.797
MDD Control G0.537 0.476 0.502 G1.684 0.610
BPD G0.943 0.456 0.105 G2.039 0.154
BPD Control 0.405 0.500 0.697 G0.797 1.607
MDD 0.943 0.456 0.105 G0.154 2.039
TOLLIP Control MDD 0.123 0.149 0.689 G0.235 0.481
BPD G0.016 0.133 0.992 G0.335 0.303
MDD Control G0.123 0.149 0.689 G0.481 0.235
BPD G0.139 0.156 0.649 G0.515 0.237
BPD Control 0.016 0.133 0.992 G0.303 0.335












































S1: Real-time PCR cycle threshold values (Ct) in five reference genes in blood 
from depressed patients both at baseline and after eight weeks of treatment with 
escitalopram. Expression levels are shown as median (lines), 25th percentile to 



















S2: A graph showing the results of the NormFinder and geNorm analyses. The x-
axis shows the reference genes tested and the y-axis shows their Normfinder and 
geNorm* stability values. The lower the stability values the more stable the 
reference gene.  HPRT1 was shown to be the most stable reference genes 
following escitalopram treatment, and B2M the most unstable reference gene. 













S3: Table detailing the top gene expression differences between responders and 
non-responders at week 0 and week 8 and their correlation with the expression 
of TNF at each week. R-values represent the correlation obtained from a two-
direction Pearson’s correlation test, and the p-values the significance of the 
correlation. 
 
 
 
 
 
